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Summary
Since publication of CDC’s 1993 guidelines (CDC. Recommendations for the prevention and management of Chlamydia
trachomatis infections, 1993. MMWR 1993;42[No. RR-12]:1–39), nucleic acid amplification tests (NAATs) have been
introduced as critical new tools to diagnose and treat C. trachomatis and Neisseria gonorrhoeae infections. NAATs for
C. trachomatis are substantially more sensitive than previous tests. When using a NAAT, any sacrifice in performance when urine
is substituted for a traditional swab specimen is limited, thus reducing dependence on invasive procedures and expanding the
venues where specimens can be obtained. NAATs can also detect both C. trachomatis and N. gonorrhoeae organisms in the same
specimen. However, NAATs are usually more expensive than previous tests, making test performance from an economic perspective
a key consideration.
This report updates the 1993 guidelines for selecting laboratory tests for C. trachomatis with an emphasis on screening men
and women in the United States. (In this report, screening refers to testing persons in the absence of symptoms or signs indicating
C. trachomatis or N. gonorrhoeae infection.) In addition, these guidelines consider tests from an economic perspective and
expand the previous guidelines to address detection of N. gonorrhoeae as well as C. trachomatis infections. Because of the
increased cost of NAATs, certain laboratories are modifying manufacturers’ procedures to improve test sensitivity without incur-
ring the full cost associated with screening with a NAAT. Such approaches addressed in these guidelines are pooling of specimens
before testing with a NAAT and additional testing of specimens whose non-NAAT test result is within a gray zone. This report also
addresses the need for additional testing after a positive screening test to improve the specificity of a final diagnosis.
To prepare these guidelines, CDC staff identified pertinent concerns, compiled the related literature published during 1990 or
later, prepared tables of evidence, and drafted recommendations. Consultants, selected for their expertise or disciplinary and
organizational affiliations, reviewed the draft recommendations. These final guidelines are the recommendations of CDC staff
who considered contributions from scientific consultants. These guidelines are intended for laboratorians, clinicians, and manag-
ers who must choose among the multiple available tests, establish standard operating procedures for collecting and processing
specimens, interpret test results for laboratory reporting, and counsel and treat patients.
Introduction
An estimated 3 million Chlamydia trachomatis infections occur
annually among sexually active adolescents and young adults in
the United States (1). The majority of persons with C. trachomatis
The material in this report originated in the National Center for HIV,
STD, and TB Prevention, Harold W. Jaffe, M.D., Acting Director, and the
Division of Sexually Transmitted Diseases Prevention, Harold W. Jaffe,
M.D., Acting Director; and the National Center for Infectious Diseases,
James M. Hughes, M.D., Director, and the Division of AIDS, STD, and
TB Laboratory Research, Jonathan E. Kaplan, M.D., Acting Director.
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infection are not aware of their infection because they do not
have symptoms that would prompt them to seek medical care
(2). Consequently, screening is necessary to identify and treat
this infection.
Untreated, C. trachomatis infections can lead to serious com-
plications. In certain studies, <40% of women with untreated
C. trachomatis infections experience pelvic inflammatory dis-
ease (PID) (3,4). Of these, the majority have symptoms that
are too mild or nonspecific for them to seek medical treat-
ment. Regardless of symptom severity, the consequences of
PID are severe. Of those with PID, 20% will become infertile;
18% will experience debilitating, chronic pelvic pain; and 9%
will have a life-threatening tubal pregnancy (5). C. trachomatis
infection during pregnancy leads to infant conjunctivitis and
pneumonia and maternal postpartum endometritis.
Among men, urethritis is the most common illness result-
ing from C. trachomatis infection. Complications (e.g., epid-
idymitis) affect a minority of infected men and rarely result in
sequelae. Among men who engage in receptive anal intercourse,
the rectum is a common site of C. trachomatis infection. Rec-
tal infections are usually asymptomatic, but can cause symp-
toms of proctitis or proctocolitis. C. trachomatis can cause
conjunctivitis among adults and is a cause of sexually acquired
reactive arthritis.*
Estimated tangible costs of C. trachomatis illness in the
United States exceed $2.4 billion annually (6). Also critical
are the intangible costs, including the psychological and emo-
tional injury caused by infertility and ectopic pregnancy.
As of December 2000, all 50 states and the District of
Columbia had enacted laws requiring the reporting of
C. trachomatis cases. In 2001, C. trachomatis infections were
the most commonly reported communicable infections, with
a total of 783,242 reports to CDC (7). Rates of C. trachomatis
infection for women are highest for adolescents (2,536/
100,000 among women aged 15–19 years) and young adults
(2,447/100,000 among women aged 20–24 years). These age
groups had the highest rates of infection for men as well,
although the peak rate occurred among men aged 20–24 years
(605/100,000).
Reported rates of C. trachomatis infections have risen sig-
nificantly during 1987–2001 (51–278 cases/100,000 persons)
(7). This increase is probably caused by a combination of fac-
tors, including an increased awareness of the need to screen
women for C. trachomatis infection, resulting in the initiation
of screening programs in both public and private health-care
settings, improvement in the sensitivity of diagnostic tests,
improved surveillance and reporting systems, and continued
high infection rates.
Introduction of large-scale screening programs (e.g., one
initiated in the Department of Health and Human Services
Region X [Alaska, Idaho, Oregon, and Washington] family
planning clinics in 1988) have been followed by a reduction
in C. trachomatis positivity rates by <60% (7–9). C. trachomatis
screening programs have been initiated throughout the United
States that are based on such demonstration projects.
In 2001, Neisseria gonorrhoeae was second in frequency only
to C. trachomatis among reported communicable infections
in the United States, with 361,705 reported cases (7). The age
distribution of N. gonorrhoeae infections is similar to that for
C. trachomatis infections. Also similar to C. trachomatis,
uncomplicated N. gonorrhoeae infection is usually confined to
the mucosa of the cervix, urethra, rectum, and throat;
N. gonorrhoeae infection is often asymptomatic among females;
and, if untreated, N. gonorrhoeae infection can lead to PID,
tubal infertility, ectopic pregnancy, and chronic pelvic pain
(10). N. gonorrhoeae usually causes symptomatic urethritis
among males, and occasionally results in epididymitis. Rarely,
local infection disseminates to cause an acute dermatitis teno-
synovitis syndrome, which can be complicated by arthritis,
meningitis, or endocarditis (10). Also, similar to C. trachomatis,
N. gonorrhoeae can be acquired at birth. N. gonorrhoeae neo-
natal infection can cause severe conjunctivitis, which can
result in blindness if untreated and, rarely, sepsis with associ-
ated meningitis, endocarditis, or arthritis. After the introduc-
tion of a national control program in the mid-1970s, the overall
rate of reported N. gonorrhoeae infection had declined by 74%
during 1975–1997 (7,11). However, the rate increased by 8.1%
during 1997–1999, followed by a limited decline in 2000–2001.
Culture testing for C. trachomatis and N. gonorrhoeae has
been the reference standard against which all other tests have
been compared. However, other tests have been needed
because culture methods for C. trachomatis are difficult to stan-
dardize, technically demanding, and expensive. Culture for
either agent is associated with problems in maintaining the
viability of organisms during transport and storage in the
diverse settings in which testing is indicated. Thus, diagnostic
test manufacturers have developed nonculture tests that do
not require viable organisms, including tests that can be
automated. The first nonculture screening tests for
C. trachomatis and N. gonorrhoeae included enzyme immu-
noassays (EIAs), which detect specific chlamydial or gono-
coccal antigens, and direct fluorescent antibody (DFA) tests
for C. trachomatis, which use fluorescein-conjugated mono-
clonal antibodies that bind specifically to bacterial antigen in
smears. These antigen-detection tests were followed by nucleic
acid hybridization tests, which detect C. trachomatis-specific
or N. gonorrhoeae-specific deoxyribonucleic acid (DNA) or
* These guidelines do not address trachoma and lymphogranuloma venereum,
which rarely occur in the United States.
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ribonucleic acid (RNA) sequences. With the availability of
these nonculture tests, screening programs for C. trachomatis
were initiated, and screening programs for N. gonorrhoeae
began to change from culture to using the more convenient
and, in remote settings, more reliable nonculture methods.
The primary drawback of these tests, chiefly for C. trachomatis,
is that they fail to detect a substantial proportion of infections
(12–23). Consequently, a new generation of nonculture tests,
called nucleic acid amplification tests (NAATs), were devel-
oped that amplify and detect C. trachomatis-specific or
N. gonorrhoeae-specific DNA or RNA sequences. These tests
are substantially more sensitive than the first generation
nonculture tests (12–23).
These guidelines are intended to assist laboratorians, clini-
cians, and managers 1) select screening tests for C. trachomatis
or N. gonorrhoeae from the complex array of tests available;
2) establish standard operating procedures for collecting, pro-
cessing, and analyzing specimens; and 3) interpret test results
for laboratory reporting, counseling, and treating patients. The
guidelines were developed through literature reviews and
extended consultation with non-CDC sexually transmitted
disease (STD) specialists.
Testing Technologies
The following discussion is a review of the complex array of
technologies now available for laboratory diagnosis of
C. trachomatis and N. gonorrhoeae infections. For this report,
technologies are subdivided into those that are designed for
1) batch testing in a laboratory or 2) point-of-care testing as
single tests or a limited number of tests performed while
patients await results. Laboratory-based tests include culture,
NAATs, nucleic acid hybridization and transformation tests,
EIAs, and DFA tests. Point-of-care tests have long included
the Gram-stained smear for N. gonorrhoeae. Point-of-care tests
for C. trachomatis include solid-phase EIAs and a solid-phase
optical immunoassay. The leukocyte esterase test (LET) is a
dipstick test that is applied to urine specimens to screen for
urinary tract inflammation (see Methods To Enhance Perfor-
mance or Reduce Costs). Personnel, quality assurance, and
quality control requirements relating to the use of all tests for
medical care are published in the Clinical Laboratory Improve-
ment Amendments of 1988 (CLIA) regulations (24) and are
linked to testing complexity.
Laboratory-Based Tests
Culture Tests
C. trachomatis Culture. Cell culture for C. trachomatis
involves inoculating a confluent monolayer of susceptible cells
with an appropriately collected and transported specimen.
After 48–72 hours of growth, infected cells develop charac-
teristic intracytoplasmic inclusions that contain substantial
numbers of C. trachomatis elementary and reticulate bodies.
These unique inclusions are detected by staining with a
fluorescein-conjugated monoclonal antibody that is specific
for the major outer membrane protein (MOMP) of
C. trachomatis.
Cell culture methods vary among laboratories, leading to
probable substantial interlaboratory variation in performance
(25). For example, because of a larger inoculum and reduced
risk of cross-contamination, the shell vial method of culture is
more sensitive and specific than the 96-well microtiter plate
method (26,27). In certain laboratories, higher sensitivities
are obtained by performing a blind pass in which an inocu-
lated cell monolayer is allowed to incubate for 48–72 hours,
after which the monolayer is disrupted and used to inoculate
a fresh monolayer that is stained after another cycle of growth (28).
Tissue culture detection of C. trachomatis is highly specific
if a C. trachomatis-MOMP-specific stain is used, because
stained C. trachomatis inclusions have a unique appearance.
Less specific inclusion-detection methods using EIA, iodine,
and Giemsa are not recommended (29,30). Certain CDC
consultants believe that commercial stains employing mono-
clonal antibodies directed against lipopolysaccharide (LPS),
which are genus-specific rather than species-specific, are more
sensitive and more economical than species-specific mono-
clonal antibody stains directed against MOMP. Such stains
might be suitable for routine use, but a species-specific stain
would be preferable in situations requiring increased specificity.
The high specificity of cell culture and ability to retain the
isolate make cell culture the first choice when the results will
be used as evidence in legal investigations. In addition, cell
culture is the only method by which a clinical isolate can be
obtained for antimicrobial susceptibility testing. The relatively
low sensitivity, long turnaround time, difficulties in standard-
ization, labor intensity, technical complexity, stringent trans-
port requirements, and relatively high cost are the primary
disadvantages of cell culture isolation of C. trachomatis. Addi-
tional information regarding cell culture for C. trachomatis is
available elsewhere (14,28,31).
N. gonorrhoeae Culture. Methods of gonococcal culture
have been well-described elsewhere (12,32). Specimens are
streaked on a selective (e.g.,Thayer-Martin or Martin-Lewis)
or nonselective (e.g., chocolate agar) medium if specimens are
from nonsterile or sterile sites, respectively. Inoculated media
are incubated at 35ºC–36.5ºC in an atmosphere supplemented
with 5% CO2 and examined at 24-hour intervals for <72 hours.
Culture media for N. gonorrhoeae isolation include a base
medium supplemented with chocolatized equine or bovine
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blood to support the growth of the gonococcus; selective
media differ from routine culture media in that they contain
antimicrobial agents (i.e., vancomycin, colistin, and an anti-
fungal agent), which inhibit the growth of other bacteria and
fungi. Supplemental CO2 can be supplied by a CO2 incuba-
tor, candle-extinction jar, or CO2-generating tablets.
A presumptive identification of N. gonorrhoeae isolates re-
covered from a genital specimen on selective medium can be
made with a Gram stain and oxidase test. A presumptive iden-
tification indicates only that a Gram-negative, oxidase-positive
diplococcus (e.g., a Neisseria species or Branhamella [Moraxella]
catarrhalis) has been isolated from a specimen. Certain cocco-
bacilli, including Kingella denitrificans, might appear to be
Gram-negative diplococci in Gram-stained smears. A con-
firmed laboratory diagnosis of N. gonorrhoeae cannot be made
on the basis of these tests alone. A presumptive test result is
sufficient to initiate antimicrobial therapy, but additional tests
must be performed to confirm the identity of an isolate as N.
gonorrhoeae. Culture isolation is also suitable for nongenital
tract specimens. Using selective media is necessary if the ana-
tomic source of the specimen normally contains other bacte-
rial species.
The sensitivity of culture can be monitored (i.e., quality-
controlled) by evaluating results among males with urethral
discharge. Culture results are compared with results obtained
by using Gram-stained smear or by using nonselective
medium. Vancomycin-sensitive strains, which were relatively
common in certain areas in the past, now appear to be an
uncommon cause of false-negative cultures (10,12,33,34).
The advantages of culture are high sensitivity and specific-
ity, low cost, suitability for use with different types of speci-
mens, and the ability to retain the isolate for additional testing.
Retention of the isolate for additional testing might be indi-
cated for medicolegal purposes, antimicrobial susceptibility
determination, and subtyping of isolates. The major disad-
vantage of culture for N. gonorrhoeae is that specimens must
be transported under conditions adequate to maintain the
viability of organisms. Another disadvantage is that a mini-
mum of 24–72 hours is required from specimen collection to
the report of a presumptive culture result.
NAATs
The common characteristic among NAATs is that they are
designed to amplify nucleic acid sequences that are specific
for the organism being detected. Similar to other nonculture
tests, NAATs do not require viable organisms. The increased
sensitivity of NAATs is attributable to their ability to produce
a positive signal from as little as a single copy of the target
DNA or RNA. Commercial tests differ in their amplification
methods and their target nucleic acid sequences. The Roche
Amplicor® (manufactured by Roche Diagnostics Corporation,
Basel, Switzerland) test uses polymerase chain reaction (PCR);
the Abbott LCx® (Abbott Laboratories, Abbott Park, Illinois)
test uses ligase chain reaction (LCR); and the Becton Dickinson
BDProbeTec™ ET (Becton, Dickinson and Company,
Franklin Lakes, New Jersey) test uses strand displacement
amplification to amplify C. trachomatis DNA sequences in
the cryptic plasmid that is found in >99% of strains of
C. trachomatis. The Gen-Probe APTIMA™ (Gen-Probe, In-
corporated, San Diego, California) assay for C. trachomatis
uses transcription-mediated amplification (TMA) to detect a
specific 23S ribosomal RNA target. These nucleic acid ampli-
fication methods are also used to detect N. gonorrhoeae. The
target for the Roche Amplicor test for N. gonorrhoeae is a 201
base pair sequence within the cytosine methyltransferase gene
M:Ngo P11. The Abbott LCx test for N. gonorrhoeae detects a
48 base-pair sequence in the Opa genes, <11 copies of which
occur per cell, whereas the BDProbeTec ET for N. gonorrhoeae
detects a DNA sequence that is within the multicopy pilin
gene-inverting protein homologue. The Gen-Probe APTIMA
Combo 2 version of TMA detects the 16S ribosomal RNA
(rRNA) of N. gonorrhoeae. Additional overviews of the vari-
ous amplification methods can be found in other published
reports (16,35,36) and in materials available from the manu-
facturers.
The majority of commercial NAATs have been cleared† by
the Food and Drug Administration (FDA) to detect
C. trachomatis and N. gonorrhoeae in endocervical swabs from
women, urethral swabs from men, and urine from both men
and women. In addition, other specimens (e.g., those from
the vagina [37–50] and eye [51–53]) have been used with
satisfactory performance, although these applications have
not been cleared by FDA. Testing of rectal and oropharyngeal
specimens with NAATs has had limited evaluation and is not
recommended.
The ability of NAATs to detect C. trachomatis and
N. gonorrhoeae without a pelvic examination or intraurethral
swab specimen (for males) (e.g., by testing urine) is a key
advantage of NAATs, and this ability facilitates screening males
and females in other than traditional screening venues (e.g.,
STD and family planning clinics). A disadvantage of NAATs
is that specimens can contain amplification inhibitors that
result in false-negative results. Certain manufacturers provide
† The term cleared is used by the Food and Drug Administration (FDA) to describe
the process they use to review applications to market the class of diagnostic
tests that includes C. trachomatis and N. gonorrhoeae tests discussed in these
guidelines. The term approved is used by FDA to describe a more rigorous
process they use to review applications to market classes of diagnostic tests that
involve, for example, higher levels of risk if the test result is erroneous than is
the case for C. trachomatis or N. gonorrhoeae.
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amplification controls to detect inhibition. Selected NAATs
might be substantially less sensitive than non-NAATs when
performed on urine than when performed on endocervical
specimens (54–56) or male urethral swabs (54,56). Although
not documented by published head-to-head studies, the
majority of CDC consultants believe that non-NAATs are sub-
stantially less sensitive than NAATs when used on urine speci-
mens. The nucleic acid primers employed by commercial
NAATs for C. trachomatis are not known to cross-react with
DNA from other bacteria found in humans. However, the
primers employed by certain NAATs for N. gonorrhoeae might
cross-react with nongonococcal Neisseria species (54,56,57).
NAATs are also more susceptible than non-NAATs to false-
positive results because of contamination if strict quality con-
trol procedures are not applied.
Nucleic Acid Hybridization (Nucleic Acid
Probe) Tests
Two nucleic acid hybridization assays are FDA-cleared to
detect C. trachomatis or N. gonorrhoeae: the Gen-Probe PACE®
2 and the Digene Hybrid Capture® II assays. Both the PACE
and Hybrid Capture assays can detect C. trachomatis or
N. gonorrhoeae in a single specimen. The PACE 2C test and
the Hybrid Capture II CT/GC versions of these tests do not
differentiate between the two organisms and, when positive,
should be followed by tests for each organism to obtain an
organism-specific result. In the Gen-Probe hybridization
assays, a DNA probe that is complementary to a specific
sequence of C. trachomatis or N. gonorrhoeae rRNA hybridizes
with any complementary rRNA that is present in the speci-
men (58). A competitive probe version of the PACE 2 assay is
commercially available to augment specificity. In this version,
the test is repeated on initially positive specimens with and
without adding an unlabeled probe. The unlabeled probe com-
petitively inhibits binding of the labeled probe; a reduction in
signal when the assay is performed with the unlabeled probe is
interpreted as verification of the initial positive test result.
RNA hybridization probes in the Digene assay are specific
for DNA sequences of C. trachomatis and N. gonorrhoeae,
including both genomic DNA and cryptic plasmid DNA (59).
Technical requirements and expertise necessary for perform-
ing nucleic acid hybridization tests are similar to those for the
EIAs, which are described in this report. One of the advan-
tages of the nucleic acid hybridization tests is the ability to
store and transport specimens for <7 days without refrigera-
tion before receipt and testing by the laboratory.
Nucleic Acid Genetic Transformation Tests
The Gonostat® test (Sierra Diagnostics, Incorporated,
Sonora, California) uses a gonococcal mutant that grows when
transformed by DNA extracted from a swab specimen con-
taining N. gonorrhoeae. N. meningitidis causes false-positive
results (60). The test has received limited evaluation in
published studies (61–64), which include an evaluation of its
use with mailed specimens (62). A genetic transformation test
is not available for detection of C. trachomatis infection.
EIA Tests
A substantial number of EIA tests have been marketed for
detecting C. trachomatis infection. By contrast, the perfor-
mance and cost characteristics of EIA tests for N. gonorrhoeae
infection have not made them competitive with culture (32).
C. trachomatis EIA tests detect chlamydial LPS with a mono-
clonal or polyclonal antibody that has been labeled with an
enzyme. The enzyme converts a colorless substrate into a col-
ored product, which is detected by a spectrophotometer. Speci-
mens can be stored and transported without refrigeration and
should be processed within the time indicated by the manu-
facturer. One disadvantage of the EIA methods that detect
LPS is the potential for false-positive results caused by cross-
reaction with LPS of other microorganisms, including other
Chlamydia species (28,30,65,66). Manufacturers have devel-
oped blocking assays that verify positive EIA test results. The
test is repeated on positive specimens with the addition of a
monoclonal antibody specific for chlamydia LPS. The mono-
clonal antibody competitively inhibits chlamydia-specific
binding by the enzyme-labeled antibody; a negative test result
when using the blocking antibody is interpreted as verifica-
tion of the initial positive test result. EIA tests should not be
used with rectal specimens because of cross-reactions with fe-
cal bacteria.
DFA Tests
Depending on the commercial product used, the antigen
that is detected by the antibody in the C. trachomatis DFA
procedure is either the MOMP or LPS molecule. Specimen
material is obtained with a swab or endocervical brush, which
is then rolled over the specimen well of a slide. After the slide
has dried and the fixative applied, the slide can be stored or
shipped at ambient temperature. The slide should be processed
by the laboratory in <7 days after the specimen has been
obtained. Staining consists of covering the smear with
fluorescein-labeled monoclonal antibody that binds to
C. trachomatis elementary bodies. Stained elementary bodies
are then identified by fluorescence microscopy. Only
C. trachomatis organisms will stain with the anti-MOMP
antibodies used in commercial kits. The anti-LPS monoclonal
antibodies used in certain commercial kits can cross-react with
nonchlamydial bacterial species, as well as with LPS of
C. pneumoniae and C. psittaci. DFA with a C. trachomatis-
specific anti-MOMP monoclonal antibody is considered
to be highly specific, when performed by an experienced
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microscopist. An additional advantage of DFA is that the
quality of endocervical smears can be assessed by checking for
the presence of columnar cells (see Collecting and Transport-
ing Specimens for Screening). DFA requires that the labora-
torian be competent in fluorescent microscopy and adequately
trained in identifying fluorescein-stained C. trachomatis
elementary bodies. DFA is best suited for laboratories that
test a limited number of specimens, because the procedure is
fatiguing and time-consuming. DFA tests have not been
established as an initial test for the direct detection of
N. gonorrhoeae in clinical specimens.
Serology Tests
Serology has limited value in testing for uncomplicated geni-
tal C. trachomatis infection and should not be used for screen-
ing because previous chlamydial infection frequently elicits
long-lasting antibodies that cannot be easily distinguished from
the antibodies produced in a current infection. More specific
information regarding serologic assays for C. trachomatis anti-
body has been reported elsewhere (14). A serologic screening
or diagnostic assay is not available for N. gonorrhoeae.
Point-of-Care Tests
C. trachomatis Point-of-Care Tests
Tests for C. trachomatis have been developed that can be
performed within 30 minutes, do not require expensive or
sophisticated equipment, and are packaged as single units. The
results are read qualitatively. These so-called rapid or stat tests
can offer advantages in physicians’ offices, small clinics and
hospitals, detention centers, and other settings where results
are needed immediately (e.g., when decisions need to be made
regarding additional testing or treatment while the patient is
still present). These tests are classified under CLIA as tests of
moderate complexity (24). Accordingly, personnel standards,
quality control, quality assurance, and proficiency testing
requirements apply when performing FDA-cleared
C. trachomatis tests that are rapid enough to qualify as point-
of-care tests. In addition, these tests are usually less sensitive
and more expensive than laboratory-based C. trachomatis tests
that require longer to perform. Similar to EIAs, these tests use
antibodies against LPS that detect all three Chlamydia species
that infect humans and are subject to the same potential for
false-positive results caused by cross-reactions with other
microorganisms. A point-of-care test should not be selected if
it is performed in a laboratory after the patient’s visit. Such
use of point-of-care tests is inappropriate because sensitivity
and specificity are typically less, controls less rigorous, and
costs higher than for tests designed for laboratory use (67).
Gram Stain for N. gonorrhoeae
Gram stain is a key tool for the diagnosis of gonococcal
urethritis in men, but its application to screening is limited
because of the requirement for an intraurethral swab speci-
men if discharge is not present at the urethral meatus. A Gram
stain for the presumptive diagnosis of N. gonorrhoeae infec-
tion is performed on thin smears of urethral exudate from
men and is presumptively positive if the smear contains typi-
cal Gram-negative diplococci within polymorphonuclear
(PMN) leukocytes. Unfortunately, other Neisseria species have
a similar appearance. Although commensal Neisseria species
are not normal flora of anogenital sites, isolates of Neisseria
meningitidis and nonpathogenic Neisseria species have been
reported occasionally from anogenital sites among both men
and women (12).
As a point-of-care test, Gram stain is most reliable for the
presumptive identification of N. gonorrhoeae in urethral exu-
dates from men. The sensitivity and specificity of a Gram stain
for males with symptomatic urethritis are comparable to cul-
ture isolation followed by oxidase testing and Gram staining
of the isolate (32,68,69). Gram-negative extracellular diplo-
cocci without any intracellular diplococci might be observed
in smears from men with early symptomatic infections. The
sensitivity of Gram stain for males with asymptomatic ure-
thral infection has not been determined. Gram-negative
intracellular diplococci might be observed with certain infections
caused by nongonococcal Neisseria species (e.g., N. cinerea).
The sensitivity of Gram stains of endocervical specimens is
lower than for urethral specimens from men with symptom-
atic gonorrhea (10,32,69), and adequate specificity requires a
skilled microscopist. For these reasons, Gram stain is not rec-
ommended for testing for N. gonorrhoeae infection among
women. Gram stains of pharyngeal specimens are not recom-
mended because N. meningitidis and commensal Neisseria spe-
cies colonize the pharynx (12). As with point-of-care tests for
C. trachomatis, the Gram-stained smear is classified under CLIA
as a moderate complexity test for urethral and endocervical
specimens (24). Gram stains from all other body sites are cat-
egorized as high complexity. A trained laboratorian is required
for preparing and reading high-complexity Gram-stained smears.
C. trachomatis and N. gonorrhoeae
Test Performance When Used
for Screening
Numerous evaluations of C. trachomatis and N. gonorrhoeae
tests when used for screening have been published. NAAT
sensitivities have consistently exceeded the sensitivities of
non-NAATs. However, the majority of published estimates of
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test performance are uncertain because of probable bias from
1) misclassification of study subjects’ infection status by refer-
ence standard tests; 2) using reference standard tests that are
more suitable for determining whether a study subject is
infected at one anatomic site (e.g., the endocervix) versus
determining whether the study subject is infected at any ana-
tomic site; and 3) predominance of studies of female and symp-
tomatic male patients from STD clinics who might not be
representative of populations who would be targeted for screen-
ing. Estimates of the differences in the performance of NAATs
and non-NAATs are also uncertain because only a limited
number of evaluations have been conducted that evaluated
the two sets of tests by using the same set of study subjects
(i.e., a head-to-head study).
Identifying a suitable standard for classifying study subjects
with respect to true infection status has been difficult. Cus-
tomary reference standards (e.g., culture) are highly specific
but lack sensitivity. When such standards are used, evaluated
test specificity is probably underestimated. Truly infected sub-
jects who are misclassified as uninfected by the reference stan-
dard are more likely to be determined positive (and thus,
inappropriately considered falsely positive) by the evaluated
test than are the uninfected subjects. Misclassification of evalu-
ated test results as false-positives occurs more frequently if the
evaluated test (e.g., a NAAT) is more sensitive than the refer-
ence test (e.g., culture). The majority of evaluators of
C. trachomatis and N. gonorrhoeae tests have attempted to
address this problem by using a discrepant analysis procedure.
This procedure has been strongly contested by statisticians
and clinical epidemiologists because reference tests are applied
dependent upon evaluated test results. This dependency con-
tributes a positive bias to estimates of sensitivity and does not
eliminate ambiguity regarding specificity estimates (70–75).
Identifying a reference standard that accurately classifies
study subjects who can be infected at multiple anatomic sites
is also problematic, chiefly for women. The majority of test
evaluations for women use an endocervical reference standard
only. Estimates of evaluated test sensitivity are probably higher
and specificity lower, when the reference standard for infec-
tion is based on a positive result from a single anatomic site
(e.g., an endocervical swab) rather than from multiple poten-
tially infected sites (e.g., an endocervical swab or urine speci-
mens) (54,76,77). The former standard, which produces
estimates by using a specimen from one anatomic site, can be
considered a specimen standard and addresses the concern of
test performance regarding identification of infection at that
site. The latter standard can be considered a patient standard.
The following sections summarize C. trachomatis and
N. gonorrhoeae test performance on the basis of recent test
evaluation studies, conducted without discrepant analysis, and
consultation with specialists in test evaluation.
C. trachomatis Tests for Screening
Women and Men
Sensitivity
Reviews of screening tests for C. trachomatis conclude that
sensitivities of commercial NAATs exceed those of non-NAATs
(14–23). A substantial proportion of the published evalua-
tions of NAATs cited in these reviews have relied on discrep-
ant analysis. However, certain studies permit the calculation
and comparison of NAAT and non-NAAT sensitivities by
using culture as an independent reference standard. A five-
center study reported sensitivities of NAATs for endocervical
specimens that exceeded the sensitivity of a nonamplified
nucleic acid hybridization test by 19.7% (95% confidence
interval [CI] = 12.9%–26.6%) for LCR and 12.4% ( 95%
CI = 2.1%–22.7%) for PCR (78). The sensitivities of LCR
and PCR were slightly lower when performed on urine speci-
mens than on endocervical specimens (83.4% versus 91.4%
and 79.5% versus 84.0% , respectively). The sensitivity of the
nonamplified hybridization test (71.6%) was similar to that
reported in an earlier study (75.3%) that compared the hy-
bridization test, three EIAs, and a DFA performed on endocer-
vical swab specimens by using culture as the reference standard
(79). Sensitivities of the tests evaluated in that study were
61.9%–75.3%.
Culture, a NAAT (LCR), and the nonamplified hybridiza-
tion test have also been compared by using an independent
reference standard (78). For this evaluation, the reference stan-
dard was a positive PCR performed on an endocervical or
urine specimen. For endocervical swab specimens, the sensi-
tivity of LCR (85.5%) exceeded that of culture (74.7%) by
10.8% and that of the hybridization test (61.9%) by 23.6%.
For the urine specimen, the sensitivity of LCR was 80.8%.
A limited number of studies have used an independent ref-
erence standard to compare the sensitivities of tests for detec-
tion of C. trachomatis infection in asymptomatic men. One
five-center study compared LCR and PCR performed on urine
from asymptomatic males by using culture of intraurethral
swab specimens as the independent reference standard (80).
The sensitivities of LCR (84.4%) and PCR (85.4%) were similar.
The majority of C. trachomatis test evaluation specialists
consulted for these guidelines believe that the sensitivities of
the point-of-care tests for C. trachomatis are substantially less
than the sensitivities of tests with longer processing times.
However, published studies do not provide a basis for specify-
ing the magnitude of the difference.
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Specificity and Positive Predictive Value
At the prevalences of C. trachomatis infection typical of popu-
lations who are screened (e.g., 2%–10%), the specificity of
the screening test and the infection prevalence are key vari-
ables because they strongly influence the proportion of posi-
tive test results that reflect infection. The term used for this
proportion is the positive predictive value (PPV) (81,82).§
At lower prevalences, a positive screening test might need to
be followed by an additional test to ensure an adequate PPV.
Published evaluations of NAATs that have used alternative
target NAATs¶ to perform discrepant analysis have reported
increased specificities (e.g., exceeding 99.0%–99.5%); such
reports have addressed NAATs for detection of C. trachomatis
in endocervical specimens, male urethral specimens, and male
or female urine. However, statisticians and clinical epidemi-
ologists have criticized these estimation procedures also. Pub-
lished studies or studies described in package inserts that have
used DFA to perform discrepant analysis or have used culture
as the standard without performing discrepant analysis have
reported specificities of 94.1%–99.5% (75). In 1993, CDC
reported a similar range of specificities for nonamplified nucleic
acid probe and EIA tests to detect C. trachomatis (31). This
report includes a graph of PPVs associated with a test with a
sensitivity of 85% across a range of test specificities and
prevalences typical of those reported for C. trachomatis screen-
ing applications (Figure).
All positive tests should be considered presumptive evidence
of infection. Regardless of screening setting, screening loca-
tion, patient population, and patient characteristics, a false-
positive test result for C. trachomatis can have adverse medical,
social, and psychological impacts for a patient. In such a case,
consideration should be given to increasing specificity by per-
forming an additional test after a positive screening test and
requiring that both the screening test and additional test be
positive to make a diagnosis of C. trachomatis infection (83).
PPV of the diagnosis will be increased unless the screening
and additional tests are falsely positive for the same reasons
(e.g., both are mislabeled or both cross-react with a
nonchlamydial organism). However, an additional test does
not fully resolve all concerns because it might provide a false-
negative result. Because therapy for C. trachomatis is safe and
should not be delayed, therapy can be offered while awaiting
additional test results or even if the additional test is negative.
Patients with positive screening test results require counseling
regarding both the risks of delaying therapy and the possibil-
ity of a false-positive test result. Consideration should be given
to routine additional testing for persons with positive
C. trachomatis screening tests when risk factor information or
actual surveys indicate that the prevalence is low, resulting in
an inadequate PPV (e.g., <90%) (see Additional Consider-
ations in Selecting a Screening Test and also, Methods To
Enhance Performance or Reduce Costs).
N. gonorrhoeae Tests for Screening
Women and Men
Sensitivity
As for C. trachomatis, a substantial proportion of published
evaluations of NAATs for N. gonorrhoeae have relied on dis-
crepant analysis for calculation of test sensitivities, which might
have positively biased the estimates. However, a meta-analysis
of evaluations of N. gonorrhoeae summarizes sensitivity esti-
mates for those studies for which sensitivity estimates could
be based on culture as the independent reference standard (13).
By using a culture standard, sensitivities were similar for an
endocervical swab nucleic acid hybridization test (92.1%) and
an FDA-cleared NAAT (96.7%).
Package inserts for NAATs recently cleared by FDA now
include results of studies conducted by using independent ref-
erence standards without employing discrepant analysis. Two
such package inserts include the results of culture, a previ-
ously FDA-cleared NAAT, and the candidate NAAT (84,85).
When the independent reference standard for infection was a
previously FDA-cleared NAAT positive on either endocervi-
cal swab or urine specimens, the sensitivities of endocervical
swab culture were less than for the Becton Dickinson
§ For example, when a test with a specificity of 99% and a sensitivity of 85% is
used to screen a population of 10,000 patients with a C. trachomatis prevalence
of 10% (i.e., 1,000 patients have an infection), an average of 940 test results
will be positive: 850 patients with a positive result will actually be infected, and
90 will not be infected (i.e., false-positives). PPV is 850/940 = 0.904. When
this same test is used to screen 10,000 patients with a chlamydia prevalence of
only 2% (i.e., 200 patients have an infection), an average of 268 test results
will be positive: 170 patients will be infected and 98 will not. The PPV is 170/
268 = 0.634.
¶ Published evaluations of commercial NAATs have augmented reference tests
with an alternative target NAAT performed by the manufacturer that employs
the same amplification method as the commercial NAAT, except for substitution
of a different set of primers.
FIGURE. Positive predictive values of a test with a sensitivity
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BDProbeTec (83.7% versus 90.2%) and Gen-Probe APTIMA
(89.3% versus 100.0%) tests; the sensitivities of the NAATs
were lower when performed on urine than on endocervical
swabs (78.2% versus 90.2% and 91.7% versus 100.0%, re-
spectively). Compared with tests for C. trachomatis, differences
in sensitivities among NAATs, nucleic acid hybridization tests
without nucleic acid amplification, and culture are reduced
when using endocervical swabs. The exception is that culture
sensitivity can decline when transport or storage conditions
compromise organism viability. Gram-stain sensitivity is not
presented for men because Gram stain of urethral swab smears
is seldom used for screening men outside STD clinic settings,
and its performance for that purpose has not been well-evalu-
ated. Gram stain is also not widely used for screening women
because of decreased sensitivity and variable specificity.
Specificity and PPV
As with C. trachomatis, test specificities and prevalences
among populations screened for N. gonorrhoeae are key deter-
minants of PPV of positive screening test results. Reported
specificities of N. gonorrhoeae screening tests are similar to
those for C. trachomatis. Unlike C. trachomatis tests, cross-
reactivity between N. gonorrhoeae and pathogenic and non-
pathogenic Neisseria has been demonstrated for certain NAATs
(54,56,57). This cross-reactivity has not been reported for the
Abbott LCx and Gen-Probe APTIMA and PACE 2 tests.
However, nongonococcal Neisseria are infrequently recovered
from the genitourinary tract. As with C. trachomatis tests, all
positive screening tests should be considered presumptive evi-
dence of infection, and routine additional testing after a posi-
tive N. gonorrhoeae screening test result would usually be
indicated when screening among a low-prevalence popula-
tion. Prevalences of N. gonorrhoeae are usually lower than for
C. trachomatis, possibly resulting in lower PPVs. The decision
to screen and conduct additional tests after a positive screen-
ing test should be made separately for the two organisms (see
Additional Considerations in Selecting a Screening Test and
also, Methods To Enhance Performance or Reduce Costs).
Selecting Screening Tests
Multiple considerations affect the selection of a screening
test. Test sensitivity is emphasized to minimize occurrence of
false-negative tests, which can result in complications of
untreated infection and ongoing transmission. However,
additional considerations might lead to the selection of a dif-
ferent test (see Additional Considerations in Selecting a Screen-
ing Test). For example, a goal of maximizing test sensitivity to
avoid missing the opportunity to treat infected persons might
warrant tolerating a limited number of false-positive diagnoses.
However, consideration must also be given to reducing the
rate and consequences of false-positive tests and to cost (see
Methods To Enhance Performance or Reduce Costs). This
report focuses on screening applications of tests for
C. trachomatis and N. gonorrhoeae infections. This report also
contains a listing of additional indications for C. trachomatis
testing and recommendations for choice of test and type of
specimen (Appendix A); similar information for N. gonorrhoeae
is also included (Appendix B).
Performance Perspective for Selecting
Screening Tests
On the basis of sensitivity, ease of specimen collection, and
ability to assess antimicrobial susceptibility (N. gonorrhoeae),
recommendations for screening women and men for
C. trachomatis and N. gonorrhoeae genitourinary tract infec-
tions are outlined in this section. Recommended screening
tests will, compared with less sensitive tests, minimize the risk
for disease sequelae and continued transmission of infections
as a result of false-negative screening tests. Clinicians should
be aware of the potential for adverse consequences caused by
a false-positive test result (e.g., substantial psychosocial or le-
gal consequences); patients with positive results should be
counseled regarding the potential for false-positive results, and
additional testing should be considered. Because such a result
might itself be falsely negative and therapies for C. trachomatis
and N. gonorrhoeae are safe and effective, treatment might be
offered while awaiting results from additional testing or even
if an additional test is negative. At lower prevalences, consid-
eration should be given to routine additional testing after a
positive screening test. Testing strategies have been proposed
that can increase specificity and constrain costs by combining
use of NAATs and non-NAATs. A particularly promising strat-
egy called gray-zone testing involves screening with a non-
NAAT and using a lower cutoff value than that established by
the manufacturer as a criterion for a positive result. A NAAT
is then performed as an additional test when the non-NAAT
screening test results are in a zone above the new cutoff value.
This strategy could achieve greater sensitivity than would be
provided by using a non-NAAT by itself and greater specific-
ity than would be provided by the separate use of either a
non-NAAT or a NAAT, and cost less than using a NAAT by
itself. This strategy might be useful for screening among lower
prevalence populations for which both PPV and cost of
detecting an infection are of increased concern. This strategy
warrants further evaluation (see Additional Considerations in
Selecting a Screening Test and also, Methods To Enhance Per-
formance or Reduce Costs).
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Screening Women for C. trachomatis and
N. gonorrhoeae Genitourinary Tract Infections
The following recommendations are based on sensitivity,
ease of specimen collection, and ability to assess antimicrobial
susceptibility (N. gonorrhoeae) (Box 1). Additional concerns,
including cost and PPV, are addressed in subsequent sections
(see Additional Considerations in Selecting a Screening Test
and also, Methods to Enhance Performance or Reduce Costs).
C. trachomatis.
1. A C. trachomatis NAAT performed on an endocervical
swab specimen provides the highest sensitivity and might
be preferred if a pelvic examination is acceptable;
otherwise, a NAAT can be performed on urine. The
sensitivity of NAATs when using urine to detect
C. trachomatis in women is similar, or only slightly inferior,
to their sensitivity when using endocervical swabs (78,86).
By using urine as a specimen, screening persons in such
venues as family planning clinics can now be extended
beyond women undergoing pelvic examinations.
Screening can be performed also in nontraditional venues
where pelvic examinations are not performed (e.g.,
schools, jails and detention centers, and street HIV or
STD outreach programs).
2. Although less sensitive than NAATs, unamplified nucleic
acid hybridization tests, EIAs, and DFA performed on
an endocervical swab specimen are acceptable for
screening (see Methods To Enhance Performance and
Reduce Costs).
3. C. trachomatis culture performed on an endocervical swab
specimen is a suitable test for screening. Specificity of
culture tests is high; however, sensitivity is less than for
NAATs and variable because of technical complexity, lack
of standardization, and the challenge of maintaining viable
organisms.
No tests have been cleared by FDA for use with vaginal
specimens. However, studies have assessed using vaginal
specimens for screening by NAATs (37–49), including vagi-
nal specimens collected by the patient (37,38,40,42,44,47–
49). The results of these studies are promising. Unless
manufacturers obtain FDA clearance for this intended use,
individual laboratories testing vaginal specimens will need
to conduct a study to establish, rather than just to verify,
test performance characteristics to satisfy CLIA requirements
(Appendix C). The sensitivity of non-NAATs with urine or
vaginal swab specimens is suboptimal. In the case of EIAs,
specificity with vaginal swab and urine specimens is also
lower than with endocervical swab specimens (65). Such
uses of non-NAATs are not recommended.
N. gonorrhoeae.
1. An N. gonorrhoeae culture test performed on an
endocervical swab specimen might be preferred on the
basis of ease of additional testing and on the continuing
need for antimicrobial-resistance monitoring. When
culture sensitivity might be compromised because of
problems in maintaining appropriate transport and
storage conditions, a NAAT or nucleic acid hybridization
test can be performed on an endocervical swab specimen.
2. As with C. trachomatis, screening for N. gonorrhoeae can
be extended to nontraditional clinical settings by using a
NAAT performed on urine. The sensitivity of NAATs to
detect N. gonorrhoeae might be less when using urine than
when using an endocervical swab specimen (54–56). This
decrease might be greater for certain NAATs than others
(54–56).
As with C. trachomatis, no tests are FDA-cleared for use
with vaginal specimens, although a study that assessed us-
ing patient-obtained vaginal specimens for screening by
NAATs yielded promising results (50). Unless manufactur-
ers obtain FDA clearance for this intended use, laboratories
testing vaginal specimens will need to conduct a study to
establish, rather than just to verify, test performance charac-
teristics to satisfy CLIA requirements (Appendix C). The
sensitivity of non-NAAT tests to detect N. gonorrhoeae with
urine or vaginal swab specimens is suboptimal. Such uses of
non-NAATs are not recommended.
Chlamydia trachomatis
• A nucleic acid amplification test (NAAT) performed
on an endocervical swab specimen, if a pelvic examina-
tion is acceptable; otherwise, a NAAT performed on
urine.
• An unamplified nucleic acid hybridization test, an en-
zyme immunoassay, or direct fluorescent antibody test
performed on an endocervical swab specimen.
• Culture performed on an endocervical swab specimen.
Neisseria gonorrhoeae
• Culture performed on an endocervical swab specimen.
If transport and storage conditions are not conducive
to maintaining the viability of N. gonorrhoeae, a NAAT
or nucleic acid hybridization test can be performed on
an endocervical swab specimen.
• A NAAT performed on urine.
BOX 1. Tests used for screening women for genitourinary tract
infection
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Screening Men for C. trachomatis
and N. gonorrhoeae Urethral Infections
This section includes recommendations for tests for screen-
ing men for C. trachomatis and N. gonorrhoeae urethral infec-
tions. These recommendations are based on sensitivity, ease of
specimen collection, and ability to assess antimicrobial sus-
ceptibility (N. gonorrhoeae) (Box 2). Additional concerns,
including cost and PPV, are addressed in subsequent sections
(see Additional Considerations in Selecting a Screening Test
and Methods to Enhance Performance or Reduce Costs).
C. trachomatis.
1. A NAAT for C. trachomatis performed on an intraurethral
swab or urine specimen is the preferred test. According
to STD specialists, NAATs might be more sensitive for
detecting C. trachomatis infection of asymptomatic men
when performed on an intraurethral swab specimen than
on urine, although limited published evaluations
demonstrate no superiority for swab specimens
(77,87,88). However, intraurethral swab specimens are
often unacceptable to males who do not have symptoms
of urethritis (89–91). NAATs performed on urine to detect
C. trachomatis have adequate sensitivity to be used for
screening. The sensitivity of non-NAATs to detect
C. trachomatis in urine from men is too low for them to
be recommended for screening.
2. A non-NAAT or culture for C. trachomatis performed on
an intraurethral swab specimen is acceptable.
N. gonorrhoeae.
1. Culture performed on an intraurethral swab specimen is
preferred in settings where collecting such specimens is
acceptable and transport and storage conditions are
suitable for culture. Collection of exudate for
N. gonorrhoeae culture at the urethral meatus without
insertion of the swab into the urethra is sufficient when
exudate is present. Culture performed on an intraurethral
swab specimen is preferred because it facilitates additional
testing, which is critical for monitoring for antimicrobial
resistance. When culture sensitivity might be
compromised because of problems in maintaining
appropriate transport and storage conditions, a NAAT
or nucleic acid hybridization test can be performed on
an intraurethral swab specimen.
2. A NAAT or nucleic acid hybridization test performed on
an intraurethral swab specimen or a NAAT performed
on urine are acceptable tests for screening. Intraurethral
swab specimens are often unacceptable to males who do
not have symptoms of urethritis (89–91). In such cases,
NAATs performed on urine to detect N. gonorrhoeae have
adequate sensitivity for use in screening. Only a limited
number of published studies have addressed whether
NAATs perform better with urethral swab specimens than
with urine in males with asymptomatic infection. One
study of asymptomatic males reported that a NAAT was
substantially less sensitive with urine than with urethral
swabs; furthermore, NAATs were less sensitive with either
specimen among males with asymptomatic infection than
with symptomatic infection (54,56).
Screening Women or Men with Possible Rectal
or Pharyngeal Exposure to C. trachomatis
or N. gonorrhoeae Infection
Selecting tests for screening for C. trachomatis and
N. gonorrhoeae rectal or pharyngeal infections is difficult
because of limited experience with nonculture tests and
increased potential for cross-reactivity with other organisms
(Box 3).
C. trachomatis.
1. Culture isolation is acceptable for detecting C. trachomatis
in rectal or pharyngeal swab specimens. A C. trachomatis-
MOMP–specific stain should be used with culture of
rectal or pharyngeal specimens to detect C. trachomatis.
Less-specific inclusion-detection methods by using EIA,
iodine, Giemsa, or LPS-specific monoclonal antibodies,
are not recommended (29,30).
2. DFA can be performed on rectal or pharyngeal swab
specimens. A C. trachomatis-MOMP-specific stain should
be used.
N. gonorrhoeae.
1. Culture isolation is well established for detecting
N. gonorrhoeae in rectal and pharyngeal swab specimens.
After isolation from rectal or pharyngeal specimens of
BOX 2. Tests used for screening men for urethral infection
Chlamydia trachomatis
• A nucleic acid amplification test (NAAT) performed
on an intraurethral swab specimen if collecting such a
specimen is acceptable; otherwise, a NAAT performed
on urine.
• A non-NAAT or culture performed on an intraurethral
swab specimen.
Neisseria gonorrhoeae
• Culture performed on an intraurethral swab specimen
if collecting such a specimen is acceptable and trans-
port and storage conditions are suitable for culture.
• A NAAT or nucleic acid hybridization test performed
on an intraurethral swab specimen if collecting such a
specimen is acceptable; otherwise, a NAAT performed
on urine.
12 MMWR October 18, 2002
typical oxidase-positive, Gram-negative diplococci on
selective media, definitive identification of N. gonorrhoeae
requires additional testing because of the common
occurrence of other pathogenic and nonpathogenic
Neisseria species in the pharynx and their occasional
occurrence in the rectum (12,92,93) (see Methods To
Enhance Performance or Reduce Costs).
If the foregoing methods are not available, screening for
C. trachomatis and N. gonorrhoeae in rectal or pharyngeal speci-
mens is not recommended. Only limited evaluations
have been published of nonculture tests to detect C. trachomatis
or N. gonorrhoeae oropharyngeal or rectal infections (32,94,95).
Additional Considerations in Selecting
a Screening Test
In addition to test sensitivity, ease of specimen collection,
and assessment for antimicrobial susceptibility (N. gonorrhoeae),
other considerations in choosing a screening test include 1) the
relatively high cost of NAATs (i.e., economic considerations);
2) laboratory environmental changes necessary to implement
NAATs; 3) the need for additional testing to support C.
trachomatis or N. gonorrhoeae diagnoses; and 4) the likelihood
of screening-test–positive persons returning for treatment. The
ability of some tests to detect C. trachomatis and N. gonorrhoeae
in the same specimen might also affect the choice of test (see
Methods To Enhance Performance or Reduce Costs). Recom-
mendations for transporting and storing specimens must also
be considered (Appendix D).
Economic Analysis
Economic analyses can assist in selecting the optimal tests
and strategy for C. trachomatis and N. gonorrhoeae screening.
Moreover, economic analyses can be relevant for STD screen-
ing because, in the absence of symptoms or signs, the cost of
screening tests, including the costs of labor and other nonkit
costs, is often not reimbursed by insurance plans or other pay-
ers. Thus, knowing the costs and benefits of a screening
program that might not be fully reimbursed can be critical to
decision makers (Box 4).
Laboratory Environment
The laboratory must consider how candidate tests match
the laboratory environment. For example, laboratories must
satisfy the requirements for physical space, separation of work
areas (e.g., sample processing and amplification), and use of
any special equipment (e.g., biosafety cabinets) as recom-
mended by the test kit manufacturer. Differences in through-
put among different NAATs must be considered. Additional
considerations include technician time, turnaround time, tech-
nical difficulty, equipment costs, and time required to main-
tain equipment. Laboratories are encouraged to investigate
these concerns and their impact on cost-effectiveness when
choosing among the available testing methods.
Need for Additional Testing To Support
C. trachomatis or N. gonorrhoeae Diagnoses
Efforts to maximize test sensitivity to avoid missing the
opportunity to identify and treat infected persons might war-
rant tolerating a certain number of false-positive diagnoses.
However, consideration must also be given to reducing
the rate and consequences of false-positive tests. All tests,
including culture for C. trachomatis, occasionally generate false-
positive results. For these reasons, all positive tests are consid-
ered to be presumptive evidence of infection (Box 5).
Regardless of health-care provider setting, patient population,
and patient characteristics, a false-positive test result for
C. trachomatis or N. gonorrhoeae can have adverse medical,
social, and psychological impacts for a patient. In such cases,
consideration should be given to performing an additional
test to verify a positive screening test.
The potential for false-positive test results complicates the
interpretation of positive tests among patients in populations
with a low prevalence of infection. This occurs because
the proportion of total positive tests that are truly positive
(i.e., PPV) is lower among such a population. Consideration
should be given to routine additional testing for persons with
positive C. trachomatis or N. gonorrhoeae screening tests when
risk-factor information or actual surveys indicate that the preva-
lence is low, resulting in a lower PPV (e.g., <90%) (see
C. trachomatis and N. gonorrhoeae Test Performance When
Used for Screening).
Economic analysis of additional testing to increase the speci-
ficity of a screening test is problematic because the primary
benefit of such additional testing is in averting costs that are
Chlamydia trachomatis
• Culture performed on rectal or pharyngeal swab speci-
mens; a C. trachomatis-major outer membrane protein
(MOMP)-specific stain should be used.
• Direct fluorescent antibody test performed on rectal or
pharyngeal swab specimens; a C. trachomatis-MOMP-
specific stain should be used.
Neisseria gonorrhoeae
• Culture performed on rectal or pharyngeal swab speci-
mens; a selective medium should be used with addi-
tional testing on colonies of typical oxidase-positive,
Gram-negative diplococci.
BOX 3. Tests for screening women or men for rectal or
pharyngeal infection
Vol. 51 / RR-15 Recommendations and Reports 13
The information in this box is not intended as a guide to
conducting economic analyses, which is beyond the scope of
these guidelines. Resources are available that explain the theory
and process in detail.* The simplest economic analysis is a
cost-analysis in which the costs of delivering a service or op-
erating a program are determined. Cost-effectiveness analy-
sis (CEA) estimates the cost of an intervention per unit
outcome that the intervention generates (e.g., infections
treated or cases of pelvic inflammatory disease [PID] avoided).
CEA is most useful for comparing different interventions that
achieve the same outcomes.†
The terms cost-effective and cost-saving are commonly used
interchangeably, but they do not mean the same thing. For
example, if a program is cost-saving, that means the cost of
implementing a program is less than the health-care costs the
program prevents. A program is cost-effective if it uses resources
efficiently, compared with alternative uses for the same resources.§
Calculating Screening Costs and Benefits
Programs considering an economic analysis of their screen-
ing activities should consider direct medical costs, including
test kits, reagents, and specimen-collection materials. They
should also consider health-care providers’ time for collecting
specimens, administration, overhead and facilities costs, and
specimen packing and transport. The testing facility must also
consider costs incurred in changing test technology (i.e., startup
equipment, laboratory remodeling costs, or such recurring costs
as training) and any changes in number or level of staff.
To measure screening benefits, programs should consider
the savings realized through averted medical costs (e.g., costs
associated with cases of PID averted through detecting and
treating C. trachomatis and N. gonorrhoeae infections). Other
health outcomes that might be of interest are epididymitis in
men, uncured infections in men that might lead to reinfec-
tion of sex partners, and neonatal complications. Other
averted costs include indirect costs (e.g., lost productivity
because of disease) or intangible costs (e.g., patient pain and
suffering). However, the indirect and intangible costs of sexu-
ally transmitted diseases are inadequately researched.
When calculating costs and benefits of screening, programs
should define the perspective of interest (e.g., a specific pro-
vider or practice, the sexually transmitted disease [STD] pro-
gram of a state health department, a commercial laboratory, a
managed care organization, the entire health-care system, or
society). The perspective determines which costs and ben-
efits are included in the calculations. For example, a societal
perspective CEA includes all costs and benefits associated with
a program, whereas a health-care–system perspective CEA in-
cludes direct medical costs but excludes costs borne solely by
patients (e.g., transportation and lost productivity). Published
CEAs usually use one of these two perspectives.¶
An interactive computer program named SOCRATES
(Screening Optimally for Chlamydia: Resource Allocation,
Testing, and Evaluation Software) is now available at the CDC
website to aid in test selection and methods to reduce costs
for screening for C. trachomatis infection among asymptom-
atic women. SOCRATES is a simple cost-effectiveness model
that uses a broad health-care–system perspective to analyze
the costs involved in using nucleic acid amplification, nucleic
acid hybridization, and enzyme immunoassay tests, singly or
with gray-zone testing, among patient populations with posi-
tivity rates that can be set and changed by the user. Costs of
testing and treatment can also be set and changed by the user.
This program is available at http://www.cdc.gov/nchstp/dstd/
HEDIS.htm.
Role of Economic Analysis
Economic analysis should rarely be the driving force for
test selection and screening strategies, but it should be con-
sidered with other factors (e.g., test performance, ease of speci-
men collection, laboratory capacity, population prevalence,
and disease prevention goals of the screening program). Cer-
tain testing approaches that are recommended in these guide-
lines (see Methods To Enhance Performance or Reduce Costs)
are difficult to assess by using CEA, because such concerns as
the repercussions of delivering a false-positive test result to a
patient are difficult to value in monetary terms.
 * Sources: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York, NY: Oxford
University Press, 1996. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996.
 † Other common economic analyses include cost-utility and cost-benefit. Cost-utility analysis converts cost-effectiveness outcomes to quality-adjusted life years
(QALYs) or disability-adjusted life years (DALYs). Cost-utility analyses are rare in sexually transmitted diseases (STD) because the QALY or DALY impacts of STD
and their sequelae are unresearched. Cost-benefit analysis converts the outcomes achieved by a program to dollar values so that the effects of different programs (e.g.,
STD screening and environmental health) can be directly compared (Source: Haddix AC, Teutsch SM, Shaffer PA, Duñet DO. Prevention effectiveness: a guide to
decision analysis and economic evaluation. New York, NY: Oxford University Press, 1996).
 § For example, if a program incurs $1,000 for screening and treating women for C. trachomatis and, therefore, avoids $2,000 in treatment costs for PID, the program
is cost-saving. However, the program might still be cost-effective even if the program does not avert enough sequelae costs to be cost-saving. A program that has a net
cost (program costs minus averted sequelae costs) of $500/case of PID averted might be considered cost-effective, compared with the first program, although it is
more expensive, if it prevented more cases. The determination of whether such a program is cost-effective requires that a judgement be made regarding the value of
the health outcomes in question. No universally applicable rules exist.
 ¶ The choice of perspective can influence the conclusions of a cost-effectiveness analysis. In the previous example, done from a health-care–system perspective,
program costs were $1,000/woman, and averted PID costs were $2,000, making the program cost-saving. Certain PID costs (e.g., those for infertility treatments)
routinely occur after the initial infection, and the program conducting the testing might never incur them. The program doing the testing might only reduce its costs
for sequelae by $800 (for treatment of acute PID) for every $1,000 spent on screening. From the perspective of the individual program, screening might not be cost-
saving. A societal perspective provides the truest indication of the cost-effectiveness of a program, but a more limited perspective can point to the impact on a given
provider or program, including the barriers to implementation of new tests or screening programs.
Box 4. Performing an economic analysis
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intangible. These include psychosocial costs that can result
from a false-positive test result. These costs vary according to
setting and are not well-researched. The benefits of reducing
these intangible costs must be weighed against the tangible
direct costs of performing the confirmatory tests. Fortunately,
these costs apply only to patients who initially test positive
and frequently constitute only a limited proportion of total
costs per positive test, particularly in low prevalence settings
where the additional testing is typically needed (see Methods
To Enhance Performance or Reduce Costs).
Consideration of Point-of-Care Testing
Point-of-care tests for C. trachomatis screening are less sen-
sitive than laboratory-based tests but should be considered in
situations where screening-test–positive persons might fail to
return for treatment or return after substantial delays. Point-
of-care tests are not a cost-effective option if they are pro-
cessed after the patient visit because they are relatively
insensitive and require labor-intensive processing. Each health-
care provider needs to compare the sensitivities, costs, and
treatment rates for point-of-care and laboratory-based tests.
Providers need to determine whether the opportunity to pro-
vide treatment to certain patients who would otherwise go
untreated warrants the additional cost and less favorable sen-
sitivity of point-of-care testing. FDA-cleared C. trachomatis
and N. gonorrhoeae tests that can be performed rapidly enough
to qualify as point-of-care tests must be performed in a CLIA-
certified laboratory because they are classified under CLIA as
moderate complexity tests (24).
Methods To Enhance Performance
or Reduce Costs
Different approaches have been used to increase the effi-
ciency of standard screening methods. Although selective
screening is not a laboratory method, using selective screen-
ing criteria is included in the following discussion because the
predictive values and cost to detect an infection are strongly
influenced by infection prevalence. Another approach is to
use a NAAT to test specimens that yield results from an EIA
or unamplified nucleic acid probe test that fall in a zone around
the cutoff (i.e., gray zone). This technique warrants further
evaluation as a method to decrease the gap in sensitivity
between NAATs and other tests without incurring the full
additional cost of testing all specimens with a NAAT. Interest
in pooling specimens for testing by a NAAT is similarly moti-
vated. Augmenting screening tests with additional testing to
improve test specificity is of increasing importance because
C. trachomatis and N. gonorrhoeae prevalences have declined
after the introduction of screening programs and because
C. trachomatis screening has expanded into lower prevalence
populations. Using test formats (e.g., nucleic acid probe tests
or NAATs) that permit testing for both C. trachomatis and
N. gonorrhoeae might reduce costs. Finally, the urine leuko-
cyte esterase test, which has a low sensitivity but is inexpen-
sive, has been used to select specimens for testing with a specific
C. trachomatis or N. gonorrhoeae test when use of a more
sensitive initial test was not feasible.
Selective Screening To Increase the
Percentage of Positive Tests
Selecting persons for testing who are at high risk can
increase the prevalence of infection among tested persons,
thereby reducing screening costs to detect persons with
C. trachomatis infection. Symptoms or signs are not included
as screening criteria because they warrant immediate diagnos-
tic testing. Evaluations of screening algorithms for
C. trachomatis, including an algorithm recommended by CDC
in 1993 (31), have been published (96–104). The third U.S.
Preventive Services Task Force (USPSTF) reviewed this infor-
mation and published C. trachomatis screening recommenda-
tions (105) (available at http://www.ahrq.gov/clinic/
uspstfix.htm) (Appendix E). USPSTF also concluded that
satisfactory urine screening tests for men had been introduced
too recently for sufficient evidence to have been developed to
make screening recommendations. Using criteria to select
women or men to screen for N. gonorrhoeae infection has
received only limited evaluation, although the prevalence of
N. gonorrhoeae is usually lower than the prevalence of
C. trachomatis. Thus, concerns regarding the cost to detect an
BOX 5. Additional testing and patient management after a
positive screening test
• All positive screening tests should be considered pre-
sumptive evidence of infection.
• An additional test should be considered after a posi-
tive screening test if a false-positive screening test would
result in substantial adverse medical, social, or
psychological impact for a patient.
• Consideration should be given to routinely perform-
ing an additional test after a positive screening test
if the positive predictive value is considered low
(e.g., <90%).
• Patients should be counseled regarding prompt treat-
ment after a positive screening test because an addi-
tional test might be falsely negative.
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infection and PPV might be greater for N. gonorrhoeae than
for C. trachomatis (106).
Gray-Zone Testing To Improve Test
Performance
To establish the positive-negative cutoff value for a diag-
nostic test, a manufacturer attempts to achieve the highest
sensitivity while keeping the specificity at or near 100%. This
is done by setting the cutoff at the lowest level possible while
minimizing false-positive results. Certain test readings from
truly infected persons will fall below this cutoff value (false-
negatives). Often, a substantial proportion of the readings for
persons with false-negative results cluster just below the cut-
off, whereas the readings for persons with truly negative
results are clustered farther below the cutoff. Consequently, a
relatively narrow zone below the cutoff might exist within
which the proportion of readings that are from truly infected
persons is substantially higher than the proportion of readings
farther below the cutoff. The ratio of true positives to true
negatives in this zone is affected by the prevalence of infection
as well as by test performance among the tested population.
Similarly, false-positive results are clustered just above the cut-
off, whereas the readings for persons with truly positive
results are clustered farther above the cutoff. A relatively nar-
row zone above the cutoff might exist within which the pro-
portion of readings that are from truly uninfected persons is
substantially higher than the proportion of readings farther
above the cutoff. When screening test results are in these zones,
commonly called the negative and positive gray zones, respec-
tively, a laboratory has the option of retesting specimens with
another test.
By using a NAAT to retest specimens with gray-zone results
from less sensitive and less expensive screening tests, the sensi-
tivity and specificity of the screening test might be improved
at less cost than switching entirely to the NAAT. However,
such a restricted use of a NAAT might be less sensitive than
testing the entire population with a NAAT. A NAAT is also
theoretically preferable to a competition or blocking antibody
assay for additional testing of specimens from persons with
positive non-NAAT screening tests (see Additional Testing To
Improve Test Specificity). Testing strategies that combine use
of a NAAT by itself in higher prevalence populations and as
an additional test after gray-zone non-NAAT results among
lower prevalence populations warrant further evaluation. Labo-
ratories should establish feasibility, cost-effectiveness, and gray-
zone limits before implementation of the strategy.
Although gray-zone testing with a NAAT has been evalu-
ated in multiple studies (107–113), these studies have not
employed independent reference standards. In certain cases,
the second test was performed on the specimen that was tested
by the screening test. If the second test has not been cleared by
FDA for use with that type of specimen, CLIA requires that
the laboratory conduct a study to establish the performance
of the second test when conducted on the screening test speci-
men (Appendix C). This regulatory requirement is critical
because NAATs might generate more false-positive and false-
negative results when performed on specimens collected
for tests designed with less stringent protection against
contamination and amplification enzyme inhibitors. Gray-
zone testing must be evaluated in appropriately designed
research studies by using an independent reference standard
before a recommendation is made regarding its utility in
routine practice.
Pooling Specimens To Reduce Costs
Because of the high sensitivity of NAATs, pooling speci-
mens before testing for C. trachomatis and N. gonorrhoeae with
LCR and PCR has been proposed as a method of reducing
costs (114–120). Samples of individual specimens are first
combined into a pool, which is then tested by a NAAT. If the
pool is negative, all specimens forming the pool are reported
as negative. If the pool is positive, a second aliquot of each
specimen that contributed to the pool is tested individually.
The potential cost-savings with pooling increases with decreas-
ing prevalence of infection, because more specimens can be
included in a pool at lower prevalences without increasing the
probability of a pool testing positive. Available evidence indi-
cates that pooling might be a cost-effective alternative to test-
ing individual specimens with minimal if any loss of sensitivity
or specificity (114–120). However, insufficient data exist from
published, peer-reviewed studies that address the implemen-
tation or performance concerns raised by pooling to make a
recommendation concerning testing of pooled specimens.
Theoretically, pooling could either increase or decrease the
sensitivity and specificity of a NAAT compared with process-
ing individual specimens. To be reported as positive, pooled
specimens must be positive according to the pooled result and
according to the individual test. This requirement should con-
tribute an increase in specificity and a decrease in sensitivity
compared with individual testing. In addition, pooling could
reduce NAAT sensitivity because the majority of pooling pro-
tocols result in a reduced amount of an individual specimen
being tested. Moreover, pooling can permit inhibitors present
in a single specimen to cause specimens that would have been
truly positive when tested individually to be falsely negative
when tested in a pool. Such inhibition will go undetected if
an internal control for inhibition is not included when testing
pooled specimens. Conversely, dilution of specimens by pool-
ing can decrease the effect of inhibitors. Pooling adds testing
and data-recording steps that can result in errors and report-
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ing of additional false-positive or false-negative results. In
addition, pooling results in a higher number of specimens in
a run being positive. This increases the chances for sub-
optimal technique (e.g., by pipetting) to result in cross-
contamination and false-positive results.
Published studies of pooling using PCR and LCR tests for
C. trachomatis and N. gonorrhoeae are still limited, and the
majority of such studies have been conducted without
an independent reference standard. Nevertheless, published
studies indicate that pooling 4–10 urine or endocervical
specimens before testing can substantially reduce costs and
improve throughput while maintaining the high performance
characteristics associated with NAATs (114–120). Savings from
reduced reagent costs have ranged from 40% to 60%.
Because of the increased complexity of the pooling protocol,
savings in personnel time are proportionately less than the
savings in reagent costs.
In addition to these performance concerns, the following
concerns should be addressed when considering use of pooling:
• what procedures to follow when all the individual speci-
mens from a positive pool provide negative results (e.g.,
test for inhibition);
• use of internal amplification controls to detect inhibition;
• the need to inform the provider or patient that specimens
are being tested by using a pooling protocol;
• how to report test results; and
• reimbursement by third-party payers.
Because pooling is a modification of FDA-cleared procedures,
laboratories that implement pooling of patient specimens must
satisfy CLIA requirements by establishing performance speci-
fications (Appendix C).
Additional Testing To Improve Test Specificity
An additional test might be indicated for a person with a
positive screening test result, if a false-positive result would
have a serious adverse consequence (Box 5). Because treat-
ments for C. trachomatis and N. gonorrhoeae are safe and rela-
tively inexpensive, the person might wish to receive and
complete treatment while additional testing is being done, or
even if the additional test is negative. Routine additional test-
ing to improve the predictive value of a positive screening test
should be considered when the prevalence of either
C. trachomatis or N. gonorrhoeae infection is low, resulting in a
low PPV (e.g., <90%) (see C. trachomatis and N. gonorrhoeae
Test Performance When Used for Screening and also, Addi-
tional Considerations in Selecting a Screening Test).
False-positive results might occur for multiple reasons,
including the following:
• the nucleic acid target, antigen, or phenotype (e.g., colis-
tin resistance, oxidase production) detected by the test is
possessed by organisms in the specimen other than
C. trachomatis or N. gonorrhoeae;
• the detection system generates a signal in the absence of
target;
• the specimen becomes contaminated; and
• staff make data entry errors.
Approaches to detect false-positive results by applying an
additional test can be ordered by preference on the basis of
theoretical considerations (Box 6).
Theoretically, testing a second specimen with a different type
of test is least likely to confirm a false-positive result, whereas
repeating the original test on the original specimen is most
likely to do so. Using a NAAT as an additional test after a
positive non-NAAT test might be an effective and highly eco-
nomical approach that deserves additional evaluation. How-
ever, except when culture is used to obtain an isolate, a
non-NAAT should not be used as an additional test after a
NAAT because of the lower sensitivity of non-NAATs. Such
additional testing could be extended to persons with non-
NAAT screening test results in the gray zone (see Gray-Zone
Testing To Improve Test Performance). An advantage of iso-
lating the organism by culture is flexibility in the choice of
multiple additional testing procedures, and compared with
NAATs, a reduced risk of error caused by contamination dur-
ing initial or subsequent testing. Using an FDA-cleared test as
an additional test to verify the positive results of a screening
test does not by itself introduce additional requirements
under CLIA (24). However, if the additional test is performed
on the original screening test specimen and the additional test
has not been cleared by FDA for use with that type of specimen,
CLIA requirements for establishing performance characteris-
tics (24) need to be satisfied (Appendix C).
Additional Testing After a Positive C. trachomatis Screen-
ing Test. Selection of an additional test to verify a positive
C. trachomatis screening test is straightforward when a second
BOX 6. Approaches to additional testing, in order by theoretical
consideration, after a positive screening test
• Test a second specimen with a different test that uses a
different target, antigen, or phenotype and a different
format.
• Test the original specimen with a different test that
uses a different target, antigen, or phenotype and a
different format.
• Repeat the original test on the original specimen with
a blocking antibody or competitive probe.
• Repeat the original test on the original specimen.
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specimen can be collected, as when a patient returns for screen-
ing test results or when the need for additional testing can be
anticipated when the screening specimen is collected (Box 7).
Using culture with a C. trachomatis-specific anti-MOMP stain
as the additional test has the advantage of high specificity and
flexibility in choice of additional testing, if warranted. How-
ever, culture lacks sensitivity and necessitates obtaining and
maintaining a suitable sample either at the initial or a subse-
quent visit. This fact has made culture less desirable. In addi-
tion, finding a laboratory to perform culture can be
problematic. If obtaining a separate specimen for additional
testing is difficult, the additional test must perform adequately
with the transport medium used for the screening test.
Using a blocking antibody format to verify a positive EIA
screening test and using a competitive probe format to verify
a positive nucleic acid probe screening test have been the ad-
ditional tests most widely used. The blocking antibody or com-
petitive probe additional test is usually performed on the
original screening specimen. These formats have been widely
used for additional testing, despite not being the theoretically
preferred approaches. This is because approaches preferred on
theoretical grounds introduce the logistical and economic
challenges of establishing a format for the additional test that
differs from that of the screening test. Collecting a separate
specimen for the additional test also presents logistical diffi-
culties and increases cost. Studies have not been conducted to
compare application of such different approaches.
Because of the greater sensitivity of NAATs, a NAAT is the
only recommended additional test to verify a result from
another NAAT and is, potentially, a superior additional test
to verify a non-NAAT positive C. trachomatis screening test.
Except for using culture to obtain an isolate, a non-NAAT
should not be used as an additional test after a NAAT because
of the lower sensitivity of the non-NAAT. Using a NAAT as
an additional test has received limited evaluation. In particular,
determining that NAAT specificity and sensitivity are not
reduced is critical if a NAAT is performed on specimens col-
lected, transported, and possibly processed by using non-
NAAT procedures that might be less stringent with respect to
preventing contamination and inhibition of amplification
enzymes.
Manufacturers of NAATs for C. trachomatis infection have
developed alternate target (e.g., MOMP targets) versions of
their commercial tests that the manufacturers have employed
for resolving discrepant results in evaluation studies. Using
the same format for the additional test as for the screening test
offers logistical and economic advantages analogous to those
offered by the blocking antibody and competitive probe
approaches for non-NAAT tests. Such assays are not offered
commercially by NAAT manufacturers but might be in the future.
Additional Testing After a Positive N. gonorrhoeae Screen-
ing Test. Methods to confirm that Gram-negative, oxidase-
positive, bacteria isolated on a selective culture medium are
N. gonorrhoeae have been reviewed (Box 8) (12,32). Acid
production from carbohydrates and the nucleic acid probe
culture confirmation test (AccuProbe,® manufactured by
Gen-Probe, San Diego, California) are the most sensitive and
specific methods. PACE 2 is also FDA-cleared for identifying
N. gonorrhoeae.
Pure growth on subculture is required for acid production
tests, but not for the AccuProbe test. AccuProbe is not known
to cross-react with other organisms found in humans;
however, variant strains of certain pathogenic and commensal
Neisseria species can provide false-positive acid production
results, and certain strains of N. gonorrhoeae might provide
false-negative acid production results. Additional tests will be
required to differentiate between species that might produce
acid from glucose but not from maltose, sucrose, or lactose
(Appendix F) or to identify variant gonococcal isolates that
fail to produce acid from glucose.
Although nongonococcal pathogenic and commensal
Neisseria species are commonly found in the oropharynx, they
are unusual in genitourinary specimens. Either the acid pro-
duction or the nucleic acid probe methods could be used for
BOX 7. Additional testing after a positive Chlamydia
trachomatis screening test
Positive Nonnucleic Acid Amplification Tests
(Non-NAAT)
• Culture with a C. trachomatis-specific anti-MOMP
(major outer membrane protein) stain can be used
after a positive non-NAAT because of the high speci-
ficity and the flexibility for additional testing, but cul-
ture poses increased difficulties in specimen transport
and storage.
• Competitive probe and blocking antibody formats can
be used after positive nucleic acid probe tests and
enzyme immunoassays, respectively, but this approach
is less likely, theoretically, to detect a false-positive
result.
• A NAAT has high potential as an additional test after
non-NAAT tests because of the increased sensitivity;
however, this use of NAATs has received limited evaluation.
Positive NAAT
• Only another NAAT has a sufficiently high sensitivity
to serve as an additional test after a positive NAAT;
however, such an approach to additional testing has
received limited evaluation.
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routine additional testing after presumptively positive screen-
ing cultures. Requiring that both types of tests be positive
should guarantee an increased level of specificity. A detailed
discussion of problems in differentiating N. gonorrhoeae from
other Neisseria and related species is located at http://
www.cdc.gov/ncidod/dastlr/gcdir/NeIdent/Index.html. If an
isolate cannot be conclusively identified as N. gonorrhoeae at a
local laboratory, the isolate should be sent to a reference labo-
ratory (e.g., a city, county, or state public health laboratory)
for confirmation, chiefly in cases of alleged sexual assault or
rape.
Antibody tests (i.e., tests that detect gonococcal antigens)
are not recommended for detection of N. gonorrhoeae.
Coagglutination tests, which might cross-react with
nongonococcal strains, are less sensitive or specific than acid
production tests or the AccuProbe or PACE 2 tests. The
monoclonal fluorescent antibody test for N. gonorrhoeae does
not detect all gonococcal isolates and is not recommended as
the primary test for detecting N. gonorrhoeae.
Additional testing after positive nonculture screening tests
for N. gonorrhoeae involves the same approaches that are
described in the previous section for C. trachomatis. Because
verification of positive nonculture tests for N. gonorrhoeae has
received only limited evaluation and certain NAATs might
cross-react with nongonococcal Neisseria species (54,56,57),
substantial effort is warranted to arrange for culture and the
assistance of a reference laboratory if a false-positive diagnosis
of N. gonorrhoeae would have serious adverse consequences,
as in testing of children.
Reporting Test Results. When additional testing has been
performed, the laboratory should report the results of both
the screening test and the additional tests, as well as the over-
all interpretation. The laboratory has the responsibility to edu-
cate clinicians regarding the importance of all laboratory
results, including both screening and additional test results.
In particular, clinicians need to be aware of the limitations of
the additional tests, including the possibility that they yield
false-negative results when the screening test is positive.
Because serious side effects from therapies for C. trachomatis
and N. gonorrhoeae are uncommon, clinicians might recom-
mend treatment after a positive screening test for a person at
risk for infection, pending additional testing or even when a
positive screening test is not verified by additional testing.
Cotesting for C. trachomatis
and N. gonorrhoeae To Reduce Costs
Multiple tests permit testing for both organisms by using
the same specimen. The prevalence of N. gonorrhoeae is less
than C. trachomatis in the majority of areas of the United States;
however, the prevalence of each varies widely, even within such
limited areas as cities or counties. Usually, screening for
N. gonorrhoeae will not be justified unless screening for
C. trachomatis is also warranted. Decisions regarding screen-
ing for either or both organisms should not be made without
a careful evaluation of the local epidemiology of N. gonorrhoeae
and C. trachomatis.
Cotesting for C. trachomatis and N. gonorrhoeae by using
tests specially designed for such cotesting should be consid-
ered, if transport conditions would reduce the sensitivity of
N. gonorrhoeae culture or if using such tests reduces the cost.
However, provision should be made to perform an additional
test to improve test specificity whenever indicated (see Addi-
tional Testing To Improve Test Specificity) and to obtain
isolates for antimicrobial susceptibility testing in the case of a
repeated treatment failure (see Test of Cure, Treatment Fail-
ure, and Antimicrobial Resistance).
BOX 8. Additional testing after a positive Neisseria
gonorrhoeae screening test
Presumptively Positive Culture
• Acid production from carbohydrates or the Gen-Probe
AccuProbe® or PACE 2® tests are the preferred methods
to confirm that typical, Gram-negative, oxidase-
positive colonies are N. gonorrhoeae.
• Requiring that both the acid production and nucleic
acid probe methods be positive for N. gonorrhoeae en-
sures a high specificity.
Positive Nonculture Test
• Culture with confirmation as described previously is
the preferred additional test after a positive nonculture
test if specimen transport and storage conditions are
suitable.
• A competitive probe format might be used after a posi-
tive nucleic acid probe test, but this approach is less
likely, theoretically, to detect a false-positive result.
• A NAAT as an additional test after a nonculture test
has received limited evaluation, and certain NAATs
might cross-react with nongonococcal Neisseria
species.*
* Sources: Martin DH, Cammarata C, Van der Pol B, et al. Multicenter
evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG
tests for Neisseria gonorrhoeae. J Clin Microbiol 2000;38:3544–9. Van der Pol
B, Martin DH, Schachter J, et al. Enhancing the specificity of the COBAS
AMPLICOR CT/NG test for Neisseria gonorrhoeae by retesting specimens
with equivocal results. J Clin Microbiol 2001;39:3092–8. Becton Dickinson.
BDProbeTec™ ET Chlamydia trachomatis and Neisseria gonorrhoeae amplified
DNA assays [Package insert]. Sparks, MD: Becton Dickinson, 1999.
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Using LET to Select for C. trachomatis
or N. gonorrhoeae Tests
LET, which has a low sensitivity but is inexpensive, has been
used to select specimens for testing with a specific C. trachomatis
or N. gonorrhoeae test when universal testing with a more sen-
sitive initial test is not feasible. Studies have demonstrated that
using a positive LET to select patients for screening with a
more sensitive and specific test can be cost-effective. Published
studies have focused primarily on asymptomatic men and have
reported that this approach is more cost-effective when
the prevalence is low (89,91,121–124). One study (121)
determined that the negative predictive value of LET among
asymptomatic men aged >30 exceeded 98%, thereby provid-
ing support for no additional C. trachomatis testing among
that population. Among men aged <30 years, whether a nega-
tive result is a valid basis on which to exclude that population
from testing with more sensitive tests is uncertain. Because
the test does not detect either C. trachomatis or N. gonorrhoeae,
but rather nonspecific inflammatory enzymes, a positive LET
should be followed by specific tests for C. trachomatis and
N. gonorrhoeae. The importance of a positive LET that is fol-
lowed by negative tests for C. trachomatis and N. gonorrhoeae
is unknown, but could indicate infection with other organ-




Correct specimen collection and handling techniques are
critical for all methods used to identify C. trachomatis and
N. gonorrhoeae. Even diagnostic tests with the highest perfor-
mance characteristics cannot produce accurate results when
specimens submitted to the laboratory are incorrectly collected.
Recommendations for transporting and storing specimens are
summarized in this report (Appendix D).
Clinicians require training and periodic assessment to main-
tain correct technique for specimen collection (125–127). The
presence of columnar epithelial cells has been associated with
increased sensitivity in the majority of studies that evaluated
collection of endocervical specimens for C. trachomatis screen-
ing with NAATs as well as other types of tests (125–132).
How these results apply to other types of specimens is
unclear. Obtaining columnar cells is less critical for detecting
N. gonorrhoeae than for detecting C. trachomatis.
Collecting and Transporting Specimens
for Screening
Specimen Collection Recommendations
Applicable to Culture and Nonculture Tests
Although the requirement for columnar endocervical
cells applies less to N. gonorrhoeae than to C. trachomatis,
guidelines included in this report are appropriate for both
organisms (Box 9).
Specific Requirements for C. trachomatis
Culture
Swabs with plastic or wire shafts can be used to obtain speci-
mens for cell culture (133–135). Swab tips can be made of
cotton, rayon, or Dacron,® but should not be made of
calcium alginate (133–136). Swabs with wooden shafts should
not be used because the wood might contain substances that
are toxic to C. trachomatis or tissue culture cells (133–135).
As part of routine quality control, samples of each lot of swabs
that are used to collect specimens for C. trachomatis isolation
should be screened for possible inhibition of C. trachomatis
growth and toxicity to tissue culture cells.
The substitution of an endocervical brush for a swab might
increase the sensitivity of culture for endocervical specimens
from nonpregnant women (137). However, using an endocer-
vical brush might induce bleeding. Although such bleeding
does not interfere with the isolation of C. trachomatis, patients
should be advised regarding possible spotting.
When culture isolation of C. trachomatis from women is to
be performed, processing a specimen from the urethra as well
as the endocervix can increase sensitivity by 23% (138). Plac-
ing the two specimens in the same transport container is
acceptable. The viability of C. trachomatis organisms must be
maintained during transport to the laboratory (28).
• When the elapsed time between specimen collection and
inoculation is <24 hours, specimens should be stored at
4ºC and inoculated in cell culture as quickly as possible.
• When specimens cannot be inoculated in <24 hours, the
specimens should be maintained at <–70ºC.
• Specimens for culture should never be stored at –20ºC or
in frost-free freezers.
Specific Requirements for N. gonorrhoeae
Culture
Swabs with plastic or wire shafts can be used to obtain speci-
mens for culture. Swab tips can be made of rayon, Dacron, or
calcium alginate. Obtaining a second cervical specimen for
N. gonorrhoeae culture is associated with an increase in sensi-
tivity (139). Inoculating the two specimens on the same
culture plate is acceptable.
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The viability of N. gonorrhoeae organisms must be main-
tained during transport to the laboratory; therefore, the fol-
lowing recommendations are made for transporting specimens:
• Specimens should be inoculated directly onto a selective
or nonselective (if the specimen is from a sterile site)
nutritive medium (e.g., Martin-Lewis or chocolate agar
containing IsoVitaleX,® respectively).
• Specimens should be incubated at 35ºC–36.5ºC in a CO2-
enriched atmosphere immediately after collection.
• For transport to a local laboratory, placement of the
inoculated plates in a CO2-enriched atmosphere is more
critical than incubation at 35ºC–36.5ºC (140–142).
Inoculated media can be held at room temperature in a
CO2-enriched atmosphere for <5 hours without a loss of
viability.
• For transport to a remote laboratory, specimens should
be inoculated onto commercial transport media (e.g.,
JEMBEC® or Transgrow media). Inoculated media should
be incubated for 18–24 hours before being transported,
and the specimen should arrive <48 hours after collection
from the patient. Specimens should not be transported in
Stuart’s, Amies’, or other such media; specimens are
diluted and organisms might lose viability if delays in ship-
ping occur. If specimens must be transported in extreme
hot or cold conditions, the specimens should be placed in
an insulated Styrofoam® container. Detailed directions
for collection of specimens for culture of N. gonorrhoeae
have been described elsewhere (12,143,144).
Adequacy of Endocervical Specimens
Without endocervical specimen quality assurance, >10% of
specimens collected for C. trachomatis testing are probably
unsatisfactory because they contain secretions or exudate, but
lack endocervical cells (126,128,145). A substantially reduced
likelihood exists of detecting C. trachomatis in inadequate speci-
mens by all tests, including NAATs (125–132).
Assessing Endocervical Specimen Quality. Health-care
providers and laboratorians are encouraged to evaluate the ef-
fect on endocervical C. trachomatis test positivity rates of moni-
toring the endocervical columnar cell content of specimens
and then providing feedback and, as indicated, training to
clinicians. Until proven unnecessary, routine or periodic as-
sessment of endocervical specimen quality is recommended
for all types of C. trachomatis tests. A report presenting alter-
native methods of measuring specimen quality has been de-
veloped by the National Chlamydia Laboratory Committee
for the CDC-supported C. trachomatis screening program and
distributed to constituent screening programs (additional
information is available at http://www.aphl.org/
chlamydia_lab.cfm). The majority of published studies have
BOX 9. Specimen-collection guidelines
Endocervical Specimens
• Nonculture specimens should be obtained as directed
by the test manufacturer in the package insert.
• By established practice, specimens for C. trachomatis
tests are obtained after specimens for Gram-stained
smear or N. gonorrhoeae culture. When a Papanico-
laou smear is to be collected, whether specimens for
C. trachomatis or N. gonorrhoeae should be collected
first or last is unknown. Bleeding can occur when a
Papanicolaou smear is obtained first, and gross blood
interferes with certain tests for C. trachomatis and
N. gonorrhoeae.
• Before obtaining a specimen, a sponge or large swab
should be used to remove all secretions and discharge
from the cervical os.
• For nonculture tests, the swab supplied or specified
by the test manufacturer should be used.
• The appropriate swab or endocervical brush should
be inserted 1–2 cm into the endocervical canal (i.e.,
past the squamocolumnar junction). The swab should
be rotated against the wall of the endocervical canal
>2 times or for the period of time recommended by
the manufacturer. The swab should be withdrawn with-
out touching any vaginal surfaces and placed in the
appropriate transport medium.
Urethral Specimens
• Specimens should be obtained as directed by the test
manufacturer in the package insert.
• If possible, obtaining specimens should be delayed until
>1 hour after the patient has voided.
• Specimens should be obtained for C. trachomatis tests
after obtaining specimens for a Gram-stained smear
or N. gonorrhoeae culture.
• For nonculture tests, the swab supplied or specified
by the manufacturer should be used.
• The urogenital swab should be inserted gently into
the urethra (females, 1–2 cm; males, 2–4 cm). The
swab should be rotated in one direction for >1 revolu-
tions and withdrawn. For males or females with ure-
thral discharge, exudate collected from the urethral
meatus is sufficient for N. gonorrhoeae culture. An
intraurethral specimen is required for C. trachomatis
testing, regardless of the presence of exudate at the meatus.
Urine Specimens
• Specimens should be obtained as directed by the test
manufacturer in the package insert.
• If possible, specimen collection should be delayed until
>1 hour after the patient has voided.*
• First-catch urine (e.g., the first 10–30 cc voided after
initiating the stream) should be used.
* Source: Sellors J, Chernesky M, Pickard L, et al. Effect of time elapsed since
previous voiding on the detection of Chlamydia trachomatis antigens in urine.
Eur J Clin Microbiol Infect Dis 1993;12:285–9.
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categorized specimens dichotomously as either containing the
appropriate endocervical cells or not. In one study, a dose-
response association between quantity of the appropriate
endocervical cells and the C. trachomatis positivity rate was
demonstrated by using a multiple-category scale for quantity
of appropriate cells (132). This study also prescribed a sys-
tematic process for reviewing slides. Diff-Quick stain has been
described as efficient and inexpensive (125).
The principal purpose of assessing the quality of endocervi-
cal specimens is to determine whether the sensitivity of
C. trachomatis tests would be enhanced by providing feedback
and training to clinicians. No evaluations have been published
of the cost-effectiveness of alternative approaches to measur-
ing the quality of endocervical cell specimens and improving
specimen-collection practices, and no studies have correlated
measures of specimen adequacy with test positivity for speci-
mens collected for N. gonorrhoeae testing.
Reporting and Follow-Up of Inadequate Specimens. An
inadequate specimen should be reported as inadequate. When-
ever possible, a second specimen should be collected for
repeat testing.
Collecting Specimens for Indications
Other Than Screening
Anatomic site-specific recommendations for application of
C. trachomatis and N. gonorrhoeae tests, including for medi-
colegal applications, are summarized in this report (Appendices
A and B). Multiple sources provide directions for collecting
specimens for N. gonorrhoeae testing (12,143,144).
Laboratory Implementation
of NAATS
NAATs require more attention to procedural details and
development and maintenance of quality control systems than
other nonculture screening tests (e.g., EIAs and nonamplified
nucleic acid hybridization assays). An increase in such require-
ments results from the susceptibility of NAAT amplification
enzymes to inhibition and the potential of NAATs to generate
cross-contaminating target and to detect limited quantities of
target present as a contaminant. Despite close attention to
quality control, concerns regarding consistency of test perfor-
mance and reproducibility persist, as indicated by reports of
heterogeneity of results in clinical trials (78,80) and varying
rates of reproducing positive results (146–151).
As laboratories and health-care providers transition to
amplification tests, certain critical concerns should be
addressed, including
• clinician training whenever a change occurs in the testing
method. Training should address
— indications for test use (e.g., appropriate types of speci-
mens);
— general instruction in obtaining adequate specimens
from any site and specific instruction in obtaining a
proper endocervical specimen (i.e., one that contains
endocervical cells rather than ectocervical cells or vagi-
nal material);
— requirements for storage and transport; and
— interpretation of test results.
• monitoring of specimen collection and transport and
periodic reinforcement of staff training.
• development of standard laboratory operating procedures
and quality-assurance protocols based on package inserts
and any supplementary manufacturer instructions.
Procedures and protocols should address
— adoption of prescribed work areas and specimen han-
dling procedures to avoid cross-contamination, which
is of heightened importance because of the inherent
sensitivity of amplification tests;
— use of positive and negative controls, including a posi-
tive control from culture stock or known positive clini-
cal specimens in addition to the control provided in
the commercial kit;
— trade-offs of using amplification controls to identify
inhibitors (e.g., reducing false-negative results but de-
creasing throughput); and
— creation of a data system that alerts laboratorians when
a run includes an unusual number of positive speci-
mens or when positive specimens are clustered within
a run.
• manufacturer-based training of laboratory staff with
periodic retraining.
• CLIA requirements for verifying or establishing test per-
formance characteristics. If a laboratory is adopting an
FDA-cleared test that is classified under CLIA as a high-
complexity test, CLIA requires conducting a study to verify
that the test performs according to the manufacturer’s
package insert claims (24). If the laboratory is adopting a
test that has not been cleared by FDA or is adopting a
modification of an FDA-cleared test, CLIA requires a more
extensive study to establish performance specifications,
because FDA-cleared package insert specifications are lack-
ing (24) (Appendix C).
• participation in a proficiency testing program.
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Test of Cure, Treatment Failure,
and Antimicrobial Resistance
Test-of-cure is not recommended as a routine procedure
after therapy for C. trachomatis or N. gonorrhoeae infection
with first-line CDC-recommended treatment regimens,
except after C. trachomatis therapy during pregnancy (152).
Nonculture tests that are performed <3 weeks after comple-
tion of antimicrobial therapy might be falsely positive because
of the presence of nonviable organisms; this applies in
particular to NAATs (153–160).
CDC recommends that clinicians contact their local or state
health department for guidance and to arrange for antimicro-
bial susceptibility testing of isolates from patients apparently
failing CDC-recommended therapy for C. trachomatis infec-
tion or CDC-recommended or FDA-approved therapy for
N. gonorrhoeae infection. For this purpose, a patient’s infec-
tion is considered to have failed therapy if the patient is
laboratory-test–positive for C. trachomatis or N. gonorrhoeae
after treatment and the patient provides a history of having
complied with the prescribed therapy and denies posttreat-
ment sexual exposure to an untreated or new sex partner.
Because knowledge is limited regarding the ability of
C. trachomatis to develop antimicrobial resistance, CDC
encourages health departments to inform CDC of treatment
failures and, if possible, arrange for shipment of a swab speci-
men suitable for tissue culture for test confirmation. To
report apparent C. trachomatis treatment failure, contact the
following:
Surveillance and Special Studies Section, Mail Stop E-02
Epidemiology and Surveillance Branch
Division of STD Prevention
Centers for Disease Control and Prevention
1600 Clifton Rd., N.E.
Atlanta, GA 30333
Phone: 404-639-8371
Attention: Susan Wang, M.D.
or Hillard Weinstock, M.D.
To submit specimens for C. trachomatis testing, contact the
following:
Chlamydia Laboratory
Syphilis and Chlamydia Branch, Mail Stop D-13
Centers for Disease Control and Prevention
1600 Clifton Rd., NE
Atlanta, GA 30333
Phone: 404-639-3785
Attention: John Papp, Ph.D.
CDC encourages health departments to inform CDC of
N. gonorrhoeae treatment failures and, if possible, arrange for
N. gonorrhoeae culture and testing of any isolate for suscepti-
bility to CDC-recommended regimens used to treat patients.
If susceptibility testing cannot be performed at a local or state
laboratory, isolates should be submitted to CDC as should
any isolate that is resistant to a CDC-recommended therapy.
Antimicrobial susceptibility testing should be performed ac-
cording to recommendations of the National Committee for
Clinical Laboratory Standards (NCCLS), and results should
be interpreted according to criteria designated by NCCLS. If
NCCLS has not provided criteria for resistance for a CDC-
recommended therapy (e.g., cephalosporins), an isolate is con-
sidered to be resistant if the isolate fails to meet the NCCLS
criteria for susceptibility. NCCLS might not have designated
criteria for definition of a susceptible category for antimicro-
bial agents that are used for gonorrhea treatment. When no
NCCLS criterion is available, consult http://www.cdc.gov/
ncidod/dastlr/gcdir/Resist/diskdif.html for additional infor-
mation or contact the Neisseria Reference Laboratory for fur-
ther guidance. To report apparent N. gonorrhoeae treatment
failure, contact the following:
Surveillance and Special Studies Section, Mail Stop E-02
Epidemiology and Surveillance Branch
Division of STD Prevention
Centers for Disease Control and Prevention
1600 Clifton Rd., N.E.
Atlanta, GA 30333
Phone: 404-639-8371
Attention: Susan Wang, M.D.
or Hillard Weinstock, M.D.
To submit specimens for N. gonorrhoeae testing, contact the
following:
Neisseria Reference Laboratory, Unit 31
Gonorrhea Research Branch, Mail Stop C-13
Bldg. 1 South/Room B260
Centers for Disease Control and Prevention
1600 Clifton Rd., N.E.
Atlanta, GA 30333
Attention: David Trees, Ph.D., 404-639-2134
or Joan S. Knapp, Ph.D., 404-639-3470
In addition, statewide programs should be maintained to rou-
tinely isolate gonococcal strains and monitor antimicrobial
susceptibilities to CDC-recommended therapies and to other
FDA-cleared therapies with established usage in the state.
Sexual Assault and Sexual Abuse
Detailed information concerning evaluation and treatment
of suspected victims of sexual assault or abuse can be obtained
from the 2002 STD treatment guidelines (152). Presented here
are general guidelines pertaining only to C. trachomatis and
N. gonorrhoeae infections (Box 10). Examination of victims is
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Testing to satisfy the first purpose requires a method that is
highly sensitive, whereas satisfying the second purpose requires
a method that is highly specific. Because of the health and
legal implications of test results, the additional time, labor,
and cost of performing tests that are sensitive and highly spe-
cific are justified. Using highly specific tests is critical with
preadolescent children for whom the diagnosis of a sexually
transmitted infection might lead to initiation of an investiga-
tion for child abuse. Local legal requirements and guidance
should be sought for maintaining and documenting a chain
of custody for specimens and results that might be used in a
legal investigation.
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Appendix A
Indications for Chlamydia trachomatis Testing
and Test Selection by Specimen Type
Readers are cautioned to refer to the manufacturers’ test kit inserts for specific details. Information in this appendix represents
general conditions for comparative purposes.
Endocervical swabs/urethral swabs from males




— Females: When pelvic examination is indicated




• Diseases at other anatomic locations possibly caused
by sexually acquired C. trachomatis infection




— Perihepatitis (Fitz-Hugh-Curtis syndrome)
(females)
— Proctitis
— Reactive arthritis/Reiter syndrome
— Conjunctivitis
• Not recommended for prepubertal children
Test selection
• Nucleic acid amplification tests (NAATs)
— Preferred because of high sensitivity relative to other tests
• Nonculture/non-NAAT
— Recommended when a NAAT is not available or not economical
• Culture
— Preferred when an isolate is needed (e.g., sexual abuse or treatment fail-
ure)
• Point-of-care tests
— Recommended only when the patient is likely to be lost to follow-up
and when the test will be performed while the patient waits for results
and possible treatment
• Additional testing is recommended after an initial positive screening test if
a low positive predictive value can be expected or if a false-positive result
would have serious psychosocial or legal consequences
Indication
• Used with endocervical swab to increase sensitivity




— Increases sensitivity of culture of endocervical swab for screening by
<23%*
— Among C. trachomatis-infected persons, dysuria is associated with a
high frequency of a positive urethral culture†
• Nonculture tests are not recommended
Indication




— Recommended on the basis of increased sensitivity and ease of use
— For males, sensitivity with urine has been lower than with urethral
swab in the majority of studies,§ but not all¶
— Other tests are not recommended because of low sensitivity and, in the
case of enzyme immunoassay (EIA) and lipopolysaccharide (LPS)-spe-
cific direct fluorescent antibody (DFA) tests, lower specificity
— Additional testing is recommended after an initial positive screening
test if a low positive predictive value can be expected or if
a false-positive result would have serious psychosocial or legal
consequences
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Vaginal swabs, postmenarcheal adolescents and adults
Vaginal swabs, prepubescent females
Rectal swabs
Indication
• Screening/testing of women when pelvic examina-
tion is not otherwise indicated
Test selection
• No test is recommended for use with vaginal swab specimens
— The Food and Drug Administration (FDA) has not cleared any
nonculture test for use with vaginal specimens
— NAAT
Additional review is needed before a recommendation can be made;
however, in multiple studies, sensitivity and specificity with a provider-
or client-collected vaginal swab has been similar to screening with en-
docervical or urine specimens
Additional testing is recommended after an initial positive screening
test if a low positive predictive value can be expected or if a positive
result would have serious psychosocial or legal consequences
— Culture
Not recommended for adults because of suboptimal sensitivity
— Other tests are not recommended because of low sensitivity and, in
case of EIA and LPS-specific DFA, low specificity
Indication
• Possible sexual abuse, children
Test selection
• Culture
— Preferred for possibly sexually abused children because of presence of
vaginal epithelium that is susceptible to C. trachomatis infection, high
specificity, and ability to retain isolate for additional testing
• FDA has not cleared any nonculture test for use with vaginal specimens
• NAAT
— When culture is not available, certain C. trachomatis specialists support
using a NAAT if a positive result can be verified by another NAAT
• Other tests are not recommended because of low sensitivity and, in the
case of EIA and LPS-specific DFA, low specificity
Indication
• Patients with history of receptive anal intercourse
• Proctitis
• Possible sexual abuse, children
Test selection
• Culture
— Preferred when an isolate is needed (e.g., sexual abuse)
— Sensitivity not well-defined; high specificity, especially if C. trachomatis-
specific stain is used
• DFA
— FDA-cleared for use with rectal specimens
— Limited evaluation in published studies
— Sensitivity not well-defined; potentially high specificity if C. trachomatis-
specific stain is used
• Other tests are not recommended
— NAAT
Although cross-reactivity with other rectal bacteria has not been re-
ported for NAATs, they have received only limited evaluation in pub-
lished studies
30 MMWR October 18, 2002
Indication
• Conjunctivitis among adults
• Newborns or infants
— Neonatal conjunctivitis
— Pneumonia consistent with C. trachomatis etiology
Test selection
• Culture
— Preferred, when available, because of high sensitivity and specificity
• EIA, nucleic acid probe, and DFA tests
— EIA, nucleic acid probe, and DFA tests that are FDA-cleared for use
with conjunctival specimens have had uniformly high sensitivities with
conjunctival specimens from newborns;†† evaluation studies are more
limited for conjunctival specimens from adults with conjunctivitis
— Specificities of tests on conjunctival specimens have also been high,††
although the potential for cross-reaction with other bacteria exists for
EIA and for culture and DFA if used with stains that are not specific for
C. trachomatis
• Other tests are not recommended
* Source: Jones RB, Katz BP, Van der Pol B, Caine VA, Batteiger BE, Newhall WJ. Effect of blind passage and multiple sampling on recovery of Chlamydia trachomatis
from urogenital specimens. J Clin Microbiol 1986;24:1029–33.
† Source: Paavonen J. Chlamydia trachomatis-induced urethritis in female partners of men with nongonococcal urethritis. Sex Transm Dis 1979;6:69–71.
§ Sources: Stary A, Schuh E, Kerschbaumer M, Gotz B, Lee H. Performance of transcription-mediated amplification and ligase chain reaction assays for detection of
chlamydial infection in urogenital samples obtained by invasive and noninvasive methods. J Clin Microbiol 1998;36:2666–70. Crotchfelt KA, Welsh LE, DeBonville
D, Rosenstraus M, Quinn TC. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification
PCR assay. J Clin Microbiol 1997;35:1536–40. Buimer M, van Doornum GJJ, Ching S, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by ligase
chain reaction-based assays with clinical specimens from various sites: implications for diagnostic testing and screening. J Clin Microbiol 1996;34:2395–2400.
Carroll KC, Aldeen WE, Morrison M, Anderson R, Lee D, Mottice S. Evaluation of the Abbott LCx Ligase Chain Reaction Assay for detection of Chlamydia
trachomatis and Neisseria gonorrhoeae in urine and genital swab specimens from a sexually transmitted disease clinic population. J Clin Microbiol 1998;36:1630–3.
Ferrero DV, Meyers HN, Schultz DE, Willis SA. Performance of the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay in detecting Chlamydia trachomatis in
endocervical and urine specimens from women and urethral and urine specimens from men attending sexually transmitted disease and family planning clinics. J Clin
Microbiol 1998;36:3230–3. Ossewaarde JM, van Doornum GJJ, Buimer M, Choueiri B, Stary A. Differences in the sensitivity of the Amplicor Chlamydia trachomatis
PCR assay. Genitourin Med 1997;73:207–11. Puolakkainen M, Hiltunen-Back E, Reunala T, et al. Comparison of performances of two commercially available
tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection. J Clin Microbiol 1998;36:1489–93. Stary A, Choueiri
B, Hörting-Müller I, Halisch P, Teodorowicz L. Detection of Chlamydia trachomatis in urethral and urine samples from symptomatic and asymptomatic male
patients by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 1996;15:465–71.
¶ Sources: Van der Pol B, Quinn TC, Gaydos CA, et al. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection
of Chlamydia trachomatis. J Clin Microbiol 2000;38:1105–12. Toye B, Peeling RW, Jessamine P, Claman P, Gemmill I. Diagnosis of Chlamydia trachomatis infections
in asymptomatic men and women by PCR assay. J Clin Microbiol 1996;34:1396–1400. Vincelette J, Schirm J, Bogard M, et al. Multicenter evaluation of the fully
automated COBAS AMPLICOR PCR test for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol 1999;37:74–80. Wiesenfeld HC,
Uhrin M, Dixon BW, Sweet RL. Diagnosis of male Chlamydia trachomatis urethritis by polymerase chain reaction. Sex Transm Dis 1994;21:268–71. Young H,
Moyes A, Horn K, Scott GR, Patrizio C, Sutherland S. PCR testing of genital and urine specimens compared with culture for the diagnosis of chlamydial infection
in men and women. Int J STD AIDS 1998;9:661–5.
**Source: Hammerschlag MR, Roblin PM, Gelling M, Tsumura N, Jule JE, Kutlin A. Use of polymerase chain reaction for the detection of Chlamydia trachomatis in
ocular and nasopharyngeal specimens from infants with conjunctivitis. Pediatr Infect Dis J 1997;16:293–7.
††Sources: Hammerschlag MR. Diagnosis of chlamydial infection in the pediatric population. Immunol Invest 1997;26:151–6. Hammerschlag MR. Chlamydia
trachomatis in children. Pediatr Ann 1994;23:349–53. Hammerschlag MR, Roblin PM, Gelling M, Worku M. Comparison of two enzyme immunoassays to culture
for the diagnosis of chlamydial conjunctivitis and respiratory infections in infants. J Clin Microbiol 1990;28:1725–7. Hammerschlag MR, Roblin PM, Cummings
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• Patients concerned regarding exposure during fellatio
or cunnilingus
• Newborns or infants (nasopharyngeal specimens)
— Neonatal conjunctivitis
— Pneumonia consistent with C. trachomatis
etiology




— Necessary when an isolate is needed (e.g., sexual abuse)
— Sensitivity not well-defined; high specificity, including if
C. trachomatis-specific stain is used
• DFA
— FDA-cleared for use with pharyngeal specimens
— Limited evaluation in published studies
— Sensitivity not well-defined; potentially high specificity if
C. trachomatis-specific stain is used
• Other tests are not recommended
— NAAT
Although cross-reactivity with other pharyngeal bacteria has not been
reported for NAATs, they have received only limited evaluation in pub-
lished studies**
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Appendix B
Indications for Neisseria gonorrhoeae Testing
and Test Selection by Specimen Type
Readers are cautioned to refer to the manufacturers’ test kit inserts for specific details. Information in this appendix represents
general conditions for comparative purposes.
Endocervical swabs/urethral swabs from males
Indication
• Screening
— Females: When pelvic examination is indicated




• Diseases at other anatomic locations possibly caused
by sexually acquired N. gonorrhoeae infection




— Perihepatitis (Fitz-Hugh-Curtis syndrome)
(females)
— Proctitis
— Disseminated gonococcal infections
— Conjunctivitis
• Not recommended for prepubertal children
Test selection
• Gram-stained smear as a point-of-care test for males with urethral dis-
charge
— For males with urethral discharge, the sensitivity and specificity are
similar to culture with oxidase testing and Gram-staining of any colo-
nies with N. gonorrhoeae morphology
— Culture after a positive Gram-stained smear might be useful for quality
assurance, but additional testing is not usually otherwise indicated
• Culture
— Preferred if ambient conditions during holding and transport of in-
oculated media are adequate to maintain the viability of organisms
Sensitivity and specificity of culture with additional testing
approaches or surpasses that of other tests
A culture isolate should be tested for antimicrobial resistance if a pa-
tient fails therapy
Culture allows monitoring for antimicrobial resistance
• Nucleic acid amplification tests (NAATs) or nucleic acid hybridization tests
— Recommended when conditions during holding and transport of in-
oculated culture media are not adequate to maintain the viability of
organisms
— Commercial polymerase chain reaction (PCR)* and strand displace-
ment assays† have cross-reacted with nongonococcal Neisseria; such
cross-reactivity has not been reported for commercial ligase chain reac-
tion (LCR) and unamplified probe assays
• Additional testing is recommended after an initial positive screening test if
a low positive predictive value can be expected or if a false-positive result








— Sensitivity with urine might be lower than with urethral (males) or
endocervical swabs§
— Other tests are not recommended because of low sensitivity
— Additional testing is recommended after an initial positive screening
test if a low positive predictive value can be expected because of a low
prevalence or if a false-positive result would have serious psychosocial
or legal consequences for a person
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Vaginal swabs, postmenarcheal adolescents and adults
Indication
• Screening/testing of women when pelvic examina-
tion is not otherwise indicated
Test selection
• No test is recommended for use with vaginal swab specimens.
— The Food and Drug Administration (FDA) has not cleared any
nonculture test for use with vaginal specimens
— NAAT
Additional review is needed before a recommendation can be made;
however, in one study,¶ sensitivity and specificity with a provider- or
client-collected vaginal swab was similar to screening with endocervi-
cal or urine specimens
Additional testing is recommended after an initial positive screening
test if a low positive predictive value can be expected or if a false-posi-
tive result would have serious psychosocial or legal consequences
— Culture
Not recommended for adults because of suboptimal sensitivity
— Other tests are not recommended because of low sensitivity
Vaginal swabs, prepubescent children
Indication
• Possible sexual abuse, children
Test selection
• Culture
— Preferred for possibly sexually abused children because of presence of
vaginal epithelium that is susceptible to N. gonorrhoeae infection, high
specificity, and ability to retain isolate for additional testing
• FDA has not cleared any nonculture test for use with vaginal specimens
• NAATs
— When culture is not available, certain specialists support use of a NAAT
if a positive result can be verified by another NAAT
• Other tests are not recommended because of low sensitivity and specificity
Rectal swabs
Indication
• Patients with history of receptive anal intercourse
• Proctitis




The sensitivity of culture is not well-defined; isolates that are oxidase-
positive and Gram-negative diplococci should receive additional test-
ing to verify an initial presumptive N. gonorrhoeae diagnosis, if a
false-positive result would have serious medical, psychosocial, or legal
consequences
A culture isolate should be tested for antimicrobial resistance if a pa-
tient fails therapy
• Other tests are not recommended
Pharyngeal swabs
Indication
• Patients concerned regarding exposure during fella-
tio or cunnilingus
• Newborn or infant (nasopharyngeal specimens)
— Neonatal conjunctivitis




Sensitivity of culture for pharyngeal specimens is not well-defined
Isolates that are oxidase-positive and contain Gram-negative diplococci
should receive additional testing to verify an initial presumptive N.
gonorrhoeae diagnosis because of the common occurrence of
nongonococcal Neisseria in the pharynx
A culture isolate should be tested for antimicrobial resistance if a pa-
tient fails therapy
• Other tests are not recommended
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Indication
• Conjunctivitis among adults
• Newborn or infant
— Neonatal conjunctivitis
Test selection
• Gram stain as point-of-care test
— Recommended on any synovial fluid and cerebrospinal fluid
collected for other tests and on endocervical and urethral swab speci-
mens
— Gram stain should be followed by laboratory-based testing, which is
more sensitive and specific
• Culture
— Preferred
— Blood, synovial fluid from affected joints, and, if indicated, cerebrospi-
nal fluid specimens should be inoculated onto nonselective as well as
selective media
— Swab specimens from the endocervix (adult female), vagina
(neonate), urethra (adult male), rectum, and pharynx should be inocu-
lated onto selective media
— Additional testing recommended after an initial positive test to verify
diagnosis
• No other tests are recommended
Diagnosing disseminated gonococcal infection, adults or neonates
—
* Source: Martin DH, Cammarata C, Van der Pol B, et al. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria
gonorrhoeae. J Clin Microbiol 2000;38:3544–9.
† Source: Becton Dickinson. BDProbeTec™ ET Chlamydia trachomatis and Neisseria gonorrhoeae amplified DNA assays [Package insert]. Sparks, MD: Becton
Dickinson, 2001.
§ Sources: Martin DH, Cammarata C, Van der Pol B, et al. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria
gonorrhoeae. J Clin Microbiol 2000;38:3544–9. Crotchfelt KA, Welsh LE, DeBonville D, Rosenstraus M, Quinn TC. Detection of Neisseria gonorrhoeae and
Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification PCR assay. J Clin Microbiol 1997;35:1536–40.
¶ Source: Hook EW III, Ching SF, Stephens J, Hardy KF, Smith KR, Lee HH. Diagnosis of Neisseria gonorrhoeae infections in women by using the ligase chain
reaction on patient-obtained vaginal swabs. J Clin Microbiol 1997;35:2129–32.
Conjunctival swabs
Test selection
• Gram stain as point-of-care test
— Recommended to establish a presumptive diagnosis of
N. gonorrhoeae during a patient’s visit for conjunctivitis
— Adequate sensitivity because of high concentration of organisms
— Gram stain should be followed by laboratory-based testing
because Gram-negative diplococci other than N. gonorrhoeae are occa-
sionally isolated from conjunctiva
• Culture
— Preferred
High sensitivity because of high concentration of organisms
Oxidase-positive and Gram-stain–positive bacteria other than
N. gonorrhoeae occasionally isolated from conjunctiva
Inoculation onto nonselective media might increase sensitivity
• Only a limited number, if any, nonculture tests are FDA-cleared for con-
junctival specimens
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When a test is a candidate to replace an established test, the
sensitivities and specificities of the candidate and established tests
should be compared. Recommendations for the conduct of test
evaluation studies have been reviewed elsewhere (C-1–C-4). The
imperfect sensitivity and specificity of reference standards com-
plicate evaluation of C. trachomatis and N. gonorrhoeae tests.
Discrepant analysis has been used universally to address this prob-
lem in the past. However, this approach has been criticized be-
cause of the likelihood of producing biased estimates of test
characteristics (C-5–C-8). Key to advancing the evaluation of C.
trachomatis and N. gonorrhoeae tests is the introduction of study
designs that compare candidate and established tests in the same
study by using an independent reference standard or by using
approaches that do not require designation of a reference stan-
dard. Investigation of such designs for evaluation of C. trachomatis
tests has begun (C-6,C-9–C-15).
The Clinical Laboratory Improvement Amendments of 1988
(CLIA) requires that a clinical laboratory verify or establish the
performance of a test to be used in the medical care of persons
when it is introduced into that laboratory (C-16). Verification
of performance under CLIA applies to the introduction of tests
that are Food and Drug Administration (FDA)-cleared, and the
CLIA requirement is that the laboratory demonstrate that test
performance (i.e., accuracy, precision, reportable range of results,
and appropriate normal values) in that laboratory be equivalent
to the performance claimed by the manufacturer in the FDA-
cleared package insert. Establishing performance under CLIA
applies to tests or modifications of tests that have not been FDA-
cleared for a particular use. When a modification or use of a test
has not been FDA-cleared, CLIA requires that the laboratory
establish the performance characteristics of the test for that use.
In addition to the performance specifications noted previously,
establishing performance must include determinations of ana-
lytical sensitivity and specificity, to include interfering substances.
Such verification or establishment studies are relatively straight-
forward when the candidate test performs similarly to the estab-
lished test. In such cases, the laboratory can verify or establish
performance by using the established test as the reference stan-
dard if discrepancies between the candidate and established test
are uncommon. If the candidate test performs differently from
the established test, the laboratory is faced with the economic
and logistical challenge of verifying or establishing the perfor-
mance of the candidate test by introducing an independent ref-
erence standard. If the laboratory lacks an independent reference
standard, a reference laboratory with an independent reference
standard might be enlisted to 1) blindly test a suitable sample of
verification or establishment study specimens with the reference
standard tests or 2) supply a panel of specimens previously char-
acterized by the reference laboratory. The reader is referred to
Appendix C
Conducting Studies To Evaluate Chlamydia trachomatis and Neisseria
gonorrhoeae Tests, Including Studies Required by the Regulations
of the Clinical Laboratory Improvement Amendments of 1988
for Verifying or Establishing Test Performance Characteristics
the American Society for Microbiology CUMITECH series for
detailed guidance regarding conduct of verification and estab-
lishment studies (C-17).
References
C-1. Irwig L, Tosteson ANA, Gatsonis C, et al. Guidelines for meta-analyses
evaluating diagnostic tests. Ann Intern Med 1994;120:667–76.
C-2. Noe DA. Evaluation of the medical utility of classification studies
[Chapter 4]. In: Noe DA, Rock RC, Grochow LB, Kahn SB, Perlin
E, eds. Laboratory medicine: the selection and interpretation of clinical
laboratory studies. Baltimore, MD: Williams & Wilkins, 1994:44–52.
C-3. Noe DA. Diagnostic classification [Chapter 3]. In: Noe DA, Rock
RC, Grochow LB, Kahn SB, Perlin E, eds. Laboratory medicine: the
selection and interpretation of clinical laboratory studies. Baltimore,
MD: Williams & Wilkins, 1994:27–43.
C-4. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards
in diagnostic test research: getting better but still not good. JAMA
1995;274:645–51.
C-5. Hadgu A. Bias in the evaluation of DNA-amplification tests for de-
tecting Chlamydia trachomatis. Statist Med 1997;16:1391–9.
C-6. Miller WC. Bias in discrepant analysis: when two wrongs don’t make
a right. J Clin Epidemiol 1998;51:219–31.
C-7. Lipman HB, Astles JR. Quantifying the bias associated with use of
discrepant analysis. Clin Chem 1998;44:108–15.
C-8. McAdam AJ. Discrepant analysis: how can we test a test? J Clin
Microbiol 2000;38:2027–9.
C-9. Alonzo TA, Pepe MS. Using a combination of reference tests to assess
the accuracy of a new diagnostic test. Statist Med 1999;18:2987–3003.
C-10. Miller WC. Can we do better than discrepant analysis for new diag-
nostic test evaluation? [Editorial response]. Clin Infect Dis
1998;27:1186–93.
C-11. Johnson RE, Green TA, Schachter J, et al. Evaluation of nucleic acid
amplification tests as reference tests for Chlamydia trachomatis infec-
tions in asymptomatic men. J Clin Microbiol 2000;38:4382–6.
C-12. Hadgu A, Qu Y. Biomedical application of latent class models with
random effects. Appl Statist 1998;47(Pt 4):603–16.
C-13. Qu Y, Hadgu A. Model for evaluating sensitivity and specificity for
correlated diagnostic tests in efficacy studies with an imperfect refer-
ence test. Journal of the American Statistical Association 1998;93:920–8.
C-14. Cheng H, Macaluso M, Vermund SH, Hook EW III. Relative accu-
racy of nucleic acid amplification tests and culture in detecting Chlamy-
dia in asymptomatic men. J Clin Microbiol 2001;39:3927–37.
C-15. Black CM, Marrazzo J, Johnson RE, et al. Head-to-head multicenter
comparison of DNA probe and nucleic acid amplification tests for
Chlamydia trachomatis in women with use of an improved reference
standard. J Clin Microbiol (in press).
C-16. Code of Federal Regulations. Title 42, Chapter IV, part 493—Labo-
ratory requirements.
C-17. Elder BL, Hansen SA, Kellogg JA, Marsik FJ, Zabransky RJ. Verifi-
cation and validation of procedures in the clinical microbiology labo-
ratory [31]. In: McCurdy BW, ed. CUMITECH: cumulative
techniques and procedures in clinical microbiology. Washington, DC:
American Society for Microbiology, 1997.
Vol. 51 / RR-15 Recommendations and Reports 35
Appendix D
Recommendations for Transport and Storage of Specimens for Chlamydia
trachomatis and Neisseria gonorrhoeae Testing, by Testing Procedure Type
Readers are cautioned to refer to the manufacturers’ test kit inserts for specific details. Information in this appendix represents


































• <24 hours at 4ºC
• If delayed >24 hours, freeze to
–70ºC
• Transport media†
Sucrose phosphate (2SP) or su-
crose phosphate glutamate (SPG),
supplemented with 5% fetal bo-
vine serum, 10 µg/mL gentamicin,
100 µg/mL vancomycin, and 1 µg/
mL amphotericin B
Micro test Multi-Microbe Media
(M4; manufactured by Micro Test,
Inc., Lilburn, GA)
• <5 hours
Inoculate selective or nonselective
medium and incubate at 35ºC–
36.5ºC and place immediately in
a CO2-enriched atmosphere
• 5–48 hours
Can be transported in ambient air
and temperature if inoculated me-
dium has been incubated at 35ºC–
36.5ºC in a CO2-enriched
atmosphere for 18–24 hours be-
fore transport
• Do not refrigerate
• Prepare slides immediately after
specimen collection
• Air dry and fix slide for 10 min-
utes in alcohol or acetone
• Transport to laboratory <7 days at
room temperature or 4ºC
• <24 hours at room temperature
• <5 days at 2ºC–8ºC
• Do not freeze specimens
Storage
• Frozen to –70ºC in transport
media
• Viability remains after >2
years, if frozen correctly
• Avoid storage at –20ºC or in
frost-free freezers
• Must be subcultured every
18–24 hours to maintain
viability until frozen
• Should be stored frozen to
<–70ºC in trypticase soy
broth plus 20% glycerine
• Fixed and unstained slides
can be stored at –20ºC for >2
years
• Specimens must be processed
<5 days after collection
• Storage after processing is not
applicable
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Intended Laboratory
















• <7 days at 2ºC–25ºC
• Swab must be immersed in
manufacturer-supplied medium
• <5 days at 2ºC–27ºC; <7 days if
maintained at 2ºC–8ºC
• Swab must be immersed in
manufacturer-supplied medium
or in isolation transport medium
• <24 hours at room temperature
• <5 days at 2ºC–8ºC
• Specimens can be frozen to
<–20ºC and tested <60 days af-
ter collection
• Specimens can be frozen to
–70ºC and tested <60 days
after collection
• Specimens can be frozen to
–20ºC and tested <60 days
after collection
• Manufacturer for the strand
displacement assay does not
recommend freezing specimens
 * New lots of swabs should be checked for toxicity to C. trachomatis isolation. Swabs with wooden shafts might be toxic to C. trachomatis or tissue culture cells.
 † Not intended as a compendium of commercially available transport media.
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The U.S. Preventive Services Task Force (USPSTF) has pub-
lished recommendations for screening certain groups of women
for C. trachomatis infection (E-1). The following summarizes
those recommendations:
• Routinely screen all sexually active women aged <25 years
for C. trachomatis infection, whether or not they are preg-
nant. Women and adolescents aged <20 years are at high-
est risk for chlamydial infection, but the majority of
reported data indicate that infection is prevalent among
women aged 20–25 years. More targeted screening might
be indicated by local prevalence data.
• Screening of women aged >25 years for C. trachomatis
should also be considered if they are at increased risk.
• Prevalence of C. trachomatis infection varies widely among
communities and patient populations. Knowledge of the
patient population is the best guide to developing a screen-
ing strategy. Certain risk factors should be considered,
including
— having new or multiple sex partners,*
— having a prior history of a sexually transmitted
disease,† and
— not using condoms consistently and correctly.
• Personal risk depends on the number of risk markers and
local disease prevalence. Specific risk-based protocols need
to be tested locally.
• The optimal timing of screening in pregnancy is
uncertain.
Appendix E
Chlamydia trachomatis Screening Recommendations
— Screening early in pregnancy provides increased
opportunities to improve pregnancy outcomes, includ-
ing low birth weight and premature delivery.
— Screening and treatment in the third trimester might
be more effective at preventing transmission of chlamy-
dial infection to the infant during birth by reducing
the risk for reinfection.
— The incremental benefit of repeated screening is
unknown.
• The optimal interval for screening women with a previ-
ous negative screening test is uncertain. The interval for
rescreening should be based on changes in sexual part-
ners, young age, and other C. trachomatis risk factors. If
evidence exists that a woman is at low risk for infection
(e.g., in a mutually monogamous relationship with a pre-
vious history of negative screening tests for chlamydial
infection), screening frequently might be unnecessary.
USPSTF did not address screening of women with a
C. trachomatis infection. CDC recommends that women with
C. trachomatis infection be screened 3–4 months after treat-
ment is completed (E-2).
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Appendix F
Characteristics of Neisseria and Related Species of Human Origin*
Polysaccharide
Acid from Reduction from Tributyrin
Species Glucose Maltose Lactose Sucrose Fructose of nitrate sucrose hydrolysis
N. gonorrhoeae† + – – – – – – –
N. meningitidis + + – – – – – –
N. lactamica + + + – – – – –
N. cinerae§ – – – – – – – –
N. polysaccharea + + – – – – – –
N. subflava¶ + + – V V – V –
N. sicca + + – + + – + –
N. mucosa + + – + + + + –
N. flavescens – – – – – – + –
N. elongata** – – – – – – – –
Branhamella
catarrhalis – – – – – + – +
Kingella denitrificans + – – – – + – –
* N. gonorrhoeae contains a subspecies referred to as N. kochii; isolates of this subspecies exhibit characteristics of both N. gonorrhoeae and N. meningitidis
but will be identified as N. gonorrhoeae by tests routinely used for the identification of Neisseria species.
† Symbols: +, strains typically positive but genetic mutants might be negative; –, negative; and V, strain-dependent.
§ Certain strains grow on selective media for isolation of N. gonorrhoeae.
¶ Includes biovars subflava, flava, and perflava. Neisseria subflava biovar perflava strains produce acid from sucrose and fructose and produce polysaccha-
ride from sucrose; Neisseria subflava biovar flava strains produce acid from fructose; Neisseria subflava biovar flava and Neisseria subflava biovar
subflava do not produce polysaccharide.
** Rod-shaped organism. Catalase test is weakly positive or negative compared with those of other Neisseria species (catalase positive). Results in this
table are for N. elongata subspecies elongata. Strains of N. elongata subspecies glycolytica might produce a weak acid reaction from D-glucose, are
catalase-positive, and do not reduce nitrate but do reduce nitrite. Strains of N. elongata subspecies nitroreducans (formerly CDC group M-6) might
produce a weak acid reaction from D-glucose, are catalase-negative, and reduce nitrate and nitrite.
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by CDC staff in the Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, and the Division of STD Prevention, National Center
for HIV, STD, and TB Prevention after a literature review and consultation with specialists within and outside CDC. The goal of this report is to provide guidance regarding
selecting and using laboratory tests for C. trachomatis and N. gonorrhoeae infections, with an emphasis on screening men and women in the United States. Upon completion
of this educational activity, the reader should be able to 1) describe the morbidity associated with C. trachomatis and N. gonorrhoeae infections that has resulted in
establishment of national prevention programs, 2) list the categories of tests available for detecting C. trachomatis and N. gonorrhoeae infections, 3) apply test performance
and other criteria to selecting C. trachomatis and N. gonorrhoeae screening tests, and 4) apply recommendations for implementing and using C. trachomatis and N. gonorrhoeae
screening tests.
To receive continuing education credit, please answer all of the following questions.
1. Which of the following conditions is not an adverse consequence of a
C. trachomatis or N. gonorrhoeae infection?
A. Infertility.




2. Which of the following does not apply to the recommendations of the
Third U.S. Preventive Services Task Force for screening persons for C.
trachomatis infection?
A. Sexually active women aged <25 years should be screened, unless local
data indicate otherwise.
B. Sexually active adolescent females are at lower risk than older women
(e.g., women aged 20–25 years).
C. Rescreening of women with C. trachomatis infection might be
indicated because of a high rate of reinfection.
D. Screening of men is of potential utility as a result of new screening tests,
but screening criteria have not been adequately evaluated.
3. Which of the following is an advantage of nucleic acid amplification tests?
A. Higher test sensitivity.
B. Ability to use a urine specimen.
C. Lower cost per test.
D. Ability to test for N. gonorrhoeae by using the same specimen.
E. Reduced requirements for quality assurance.
F. A, B, and D are advantages, but not C and E.
4. Which of the following statements best describes the positive
predictive value (PPV) of a diagnostic test?
A. PPV is the proportion of persons who have a positive test among those
who actually have the condition for which the test is performed.
B. PPV is the proportion of persons who actually have the condition
among all persons who have a positive test.
C. PPV is the proportion of persons who have a negative test among those
who do not have the condition.
D. PPV is the proportion of persons who do not have the condition
among all persons who have a negative test.
5. An additional test after a positive screening test for C. trachomatis or
N. gonorrhoeae infection should be considered when the . . .
A. prevalence of infection is low.
B. sensitivity of the screening test is low.
C. specificity of the screening test is not sufficiently high.
D. PPV of the screening test is thought to be low.
E. A, C, and D, but not B.
F. B, C, and D, but not A.
6. Which of the following methods of additional testing after a positive
screening test for C. trachomatis or N. gonorrhoeae infection is
theoretically most accurate?
A. Repeat the screening test on the original specimen.
B. Repeat the screening test on the original specimen with the addition of
a blocking or competition reagent.
C. Retest the original specimen with a test that identifies a different target
or trait and uses a different format than the screening test.
D. Obtain a fresh specimen and test with an alternative test that identifies
a different target or trait and uses a different format than the original
screening test.
7. Which of the following statements characterizes economic analyses
conducted to assist in selecting a screening test for C. trachomatis or
N. gonorrhoeae infection?
A. The cost of additional testing after a positive screening test is usually
only a limited proportion of the costs of screening and treatment.
B. The cost of screening tests performed in the absence of symptoms or
signs of C. trachomatis or N. gonorrhoeae infection is usually
reimbursed by insurance.
C. A screening program is cost-effective only if it is also cost-saving.
D. Economic analyses can be conducted from a societal or a health-care
provider perspective.
E. A and D, but not B and C.
F. A, C, and D, but not B.
8. Which of the following is a reason to recommend culture for the
detection of N. gonorrhoeae infection?
A. Additional testing might be required to establish a diagnosis.
B. Treatment failures have been reported because of decreased
susceptibility of N. gonorrhoeae to the antibiotic used for treatment.
C. The location for specimen collection and the laboratory are relatively
far apart geographically.
D. Given appropriate transport conditions, culture is as sensitive or
approximately as sensitive as alternative tests.
E. A, B, and D but not C.
9. Which of the following is a characteristic of point-of-care tests for C.
trachomatis infection?
A. Sensitivities of point-of-care tests are higher than tests designed to be
performed in batch after the tested person leaves.
B. Point-of-care tests are useful for increasing the percent of test-positive
persons who receive treatment.
C. A lower cost per tested person has been a principal reason for screening
with point-of-care tests.
10. Which of the following statements concerning the collection of
endocervical swab specimens for C. trachomatis tests is true?
A. Specimens for nonculture tests should be obtained by following the
directions outlined by manufacturers in package inserts.
B. Studies have reported that obtaining endocervical swab specimens
with adequate numbers of columnar epithelial cells is critical even for
nucleic acid amplification tests.
C. Clinicians require training and periodic assessment to maintain correct
endocervical specimen collection technique.
D. All of the statements are true.
11. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.




13. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
14. Each month, approximately how many patients do you test for C.






15. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 but <4.0 hours.
D. >4.0 hours.
16. After reading this report, I am confident I can describe how to select
and use laboratory tests for C. trachomatis and N. gonorrhoeae




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe the morbidity
associated with C. trachomatis and N. gonorrhoeae infections that has
resulted in the establishment of national prevention programs.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can list the categories of tests
available to detect C. trachomatis and N. gonorrhoeae infections.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–10
1. C; 2. B; 3. F; 4. B; 5. E; 6. D; 7. E; 8. E; 9. B; 10. D.
19. After reading this report, I am confident I can apply test performance




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can apply recommendations




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. The tables, boxes, and figure are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. How did you learn about this continuing education activity?
A. Internet.





All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.
——————
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health
and Human Services.
——————
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of
these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the
content of these sites. URL addresses listed in MMWR were current as of the date of publication.
Laboratory Guidelines for Screening To Detect Chlamydia trachomatis
and Neisseria gonorrhoeae Infections — 2002
Consultants
External Consultants: Association of Public Health Laboratories, Washington, D.C. (no reviewers identified); Dana Best, M.D., Agency for Healthcare
Research and Quality, Rockville, Maryland; Margaret C. Fisher, M.D., and Leonard Weiner, M.D., American Academy of Pediatrics, Elk Grove Village,
Illinois; Luella Klein, M.D., American College of Obstetricians and Gynecologists, Washington, D.C.; Roxanne Shively, Food and Drug Administration,
Rockville, Maryland; Aggie Clark, University of Washington, Seattle, Washington; Dennis V. Ferrero, M.P.H., San Joaquin County Regional Public Health
Laboratory, Stockton, California; Charlotte A. Gaydos, Dr.P.H., Johns Hopkins University, Baltimore, Maryland; Anne Haddix, Ph.D., Emory University,
Atlanta, Georgia; Margaret R. Hammerschlag, M.D., State University of New York, Brooklyn, New York; Doug R. Harger, Oregon Health Division, Portland,
Oregon; Edward W. Hook, III, M.D., University of Alabama at Birmingham, Birmingham, Alabama; J. Mehsen Joseph, Ph.D., Maryland Department of
Health and Mental Hygiene, Baltimore, Maryland; Robert B. Jones, M.D., Ph.D., Indiana University, Indianapolis, Indiana; James A. Kellogg, Ph.D., York
Hospital, York, Pennsylvania; Barry P. Katz, Ph.D., Indiana University, Indianapolis, Indiana; David H. Martin, M.D., Louisiana State University, New
Orleans, Louisiana; Toby Merlin, M.D., Lovelace Health Systems and CIGNA Healthcare of Arizona, Albuquerque, New Mexico; William C. Miller, M.D.,
Ph.D., University of North Carolina, Chapel Hill, North Carolina; Pamela G. Nathanson, Family Planning Council, Inc., Philadelphia, Pennsylvania; Albert
Rabinovitch, M.D., Ph.D., Specialty Laboratories, Inc., Santa Monica, California; Julius Schachter, Ph.D., University of California at San Francisco, San
Francisco, California; Karla Schmitt, Ph.D., Florida Department of Health, Tallahassee, Florida; Michael R. Skeels, Ph.D., Oregon State Public Health
Laboratories, Portland, Oregon; Walter E. Stamm, M.D., University of Washington, Seattle, Washington; Barbara van der Pol, Indiana University, Indianapolis,
Indiana; Jo Ann Yatabe, Ph.D., Specialty Laboratories, Inc., Santa Monica, California.
CDC Consultants: Timothy A. Green, Ph.D., Epidemiology Program Office, John R. Astles, Ph.D., Nancy L. Anderson, M.M.Sc., and Rhonda S. Whalen,
M.S., Public Health Practice Program Office.
MMWR
The Morbidity and Mortality Weekly Report (MMWR) series is prepared by the Centers for Disease Control and Prevention (CDC) and
is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send
an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from
CDC’s Internet server at http://www.cdc.gov/mmwr or from CDC’s file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. To
subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone
202-512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week
concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday.
Address inquiries about the MMWR series, including material to be considered for publication, to Editor, MMWR Series, Mailstop C-08,
CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.
All material in the MMWR series is in the public domain and may be used and reprinted without permission; however, citation of the
source is appreciated.
✩ U.S. Government Printing Office: 2003-533-155/69061 Region IV
